CN104356142B - 脱氢硫胺[2,3‑c]喹啉‑12‑酮衍生物及其制备方法和应用 - Google Patents
脱氢硫胺[2,3‑c]喹啉‑12‑酮衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN104356142B CN104356142B CN201410566281.7A CN201410566281A CN104356142B CN 104356142 B CN104356142 B CN 104356142B CN 201410566281 A CN201410566281 A CN 201410566281A CN 104356142 B CN104356142 B CN 104356142B
- Authority
- CN
- China
- Prior art keywords
- chloro
- quinoline
- ketone
- thiochromes
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Ketone derivatives of Thiochrome Chemical class 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title abstract description 4
- BXYZFBZFOPCYGD-UHFFFAOYSA-N 3-[[3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C=C(C=CC=2)C=2C3=CC=CC(=C3N=CC=2C(=O)C=2C=CC=CC=2)C(F)(F)F)=C1 BXYZFBZFOPCYGD-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 101710183280 Topoisomerase Proteins 0.000 claims abstract description 21
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 13
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 396
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 156
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 106
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 17
- 229940126214 compound 3 Drugs 0.000 claims description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 239000013049 sediment Substances 0.000 claims description 12
- 239000000376 reactant Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 7
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 229940125782 compound 2 Drugs 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims description 6
- 229960004194 lidocaine Drugs 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 229960003540 oxyquinoline Drugs 0.000 claims description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 229910019213 POCl3 Inorganic materials 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- GTQXMAIXVFLYKF-UHFFFAOYSA-N thiochrome Chemical compound CC1=NC=C2CN3C(C)=C(CCO)SC3=NC2=N1 GTQXMAIXVFLYKF-UHFFFAOYSA-N 0.000 abstract description 16
- 230000005907 cancer growth Effects 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 198
- 239000002585 base Substances 0.000 description 68
- 239000007787 solid Substances 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 55
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 35
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 24
- 108010017842 Telomerase Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 10
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 108091035539 telomere Proteins 0.000 description 8
- 210000003411 telomere Anatomy 0.000 description 8
- 102000055501 telomere Human genes 0.000 description 8
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 125000003368 amide group Chemical group 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 4
- RCPIUQUQYZVPDX-UHFFFAOYSA-N 1-(1-benzylcyclohexa-2,4-dien-1-yl)piperidine Chemical class C1C=CC=CC1(N1CCCCC1)CC1=CC=CC=C1 RCPIUQUQYZVPDX-UHFFFAOYSA-N 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical class C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 4
- 150000003053 piperidines Chemical class 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- WEJYAVWVGNXARP-UHFFFAOYSA-N 1-(4-benzylphenyl)piperidine Chemical class C1N(CCCC1)C1=CC=C(CC2=CC=CC=C2)C=C1 WEJYAVWVGNXARP-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 125000006309 butyl amino group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000009650 gentamicin protection assay Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- QWRBURIBZNRKFR-UHFFFAOYSA-N 10-chloro-6-(2-oxopiperidin-1-yl)thiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1N1CCCCC1=O QWRBURIBZNRKFR-UHFFFAOYSA-N 0.000 description 2
- IAMZXKOIZILXFB-UHFFFAOYSA-N 10-chloro-6-(2-phenylethylamino)thiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1NCCC1=CC=CC=C1 IAMZXKOIZILXFB-UHFFFAOYSA-N 0.000 description 2
- KYVZVFLTKLWTCI-UHFFFAOYSA-N 10-chloro-6-(4-ethylpiperazin-1-yl)thiochromeno[2,3-c]quinolin-12-one Chemical compound C1CN(CC)CCN1C1=NC2=CC=CC=C2C2=C1SC1=CC=C(Cl)C=C1C2=O KYVZVFLTKLWTCI-UHFFFAOYSA-N 0.000 description 2
- WXGAUZMASKLADZ-UHFFFAOYSA-N 10-chloro-6-(4-piperidin-1-ylpiperidin-1-yl)thiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1N(CC1)CCC1N1CCCCC1 WXGAUZMASKLADZ-UHFFFAOYSA-N 0.000 description 2
- BWQARODVJAANCN-UHFFFAOYSA-N 10-chloro-6-(cyclohexylamino)thiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1NC1CCCCC1 BWQARODVJAANCN-UHFFFAOYSA-N 0.000 description 2
- RGESXLHVZDISJF-UHFFFAOYSA-N 10-chloro-6-(pentan-3-ylamino)thiochromeno[2,3-c]quinolin-12-one Chemical compound S1C2=CC=C(Cl)C=C2C(=O)C2=C1C(NC(CC)CC)=NC1=CC=CC=C12 RGESXLHVZDISJF-UHFFFAOYSA-N 0.000 description 2
- VZLFCSLSONDEQE-UHFFFAOYSA-N 10-chloro-6-(piperidin-1-ylamino)thiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1NN1CCCCC1 VZLFCSLSONDEQE-UHFFFAOYSA-N 0.000 description 2
- ZLYADJCHIBOFRM-UHFFFAOYSA-N 10-chloro-6-(propylamino)thiochromeno[2,3-c]quinolin-12-one Chemical compound S1C2=CC=C(Cl)C=C2C(=O)C2=C1C(NCCC)=NC1=CC=CC=C12 ZLYADJCHIBOFRM-UHFFFAOYSA-N 0.000 description 2
- PCNVXSYOTFIZLG-UHFFFAOYSA-N 10-chloro-6-piperazin-1-ylthiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1N1CCNCC1 PCNVXSYOTFIZLG-UHFFFAOYSA-N 0.000 description 2
- RNEDRWDVZROZPC-UHFFFAOYSA-N 10-chloro-6-piperidin-1-ylthiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1N1CCCCC1 RNEDRWDVZROZPC-UHFFFAOYSA-N 0.000 description 2
- VZTYOLCXZZGMOF-UHFFFAOYSA-N 10-chloro-6-pyrrolidin-1-ylthiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1N1CCCC1 VZTYOLCXZZGMOF-UHFFFAOYSA-N 0.000 description 2
- MMTYOTMWLNZTSP-UHFFFAOYSA-N 2-(10-chloro-12-oxothiochromeno[2,3-c]quinolin-6-yl)guanidine Chemical compound S1C2=CC=C(Cl)C=C2C(=O)C2=C1C(N=C(N)N)=NC1=CC=CC=C12 MMTYOTMWLNZTSP-UHFFFAOYSA-N 0.000 description 2
- YPKLXLYGMAWXDO-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanylacetic acid Chemical compound OC(=O)CSC1=CC=C(Cl)C=C1 YPKLXLYGMAWXDO-UHFFFAOYSA-N 0.000 description 2
- CZROFSGVHASLQK-UHFFFAOYSA-N 6-(2-aminoethylamino)-10-chlorothiochromeno[2,3-c]quinolin-12-one Chemical compound S1C2=CC=C(Cl)C=C2C(=O)C2=C1C(NCCN)=NC1=CC=CC=C12 CZROFSGVHASLQK-UHFFFAOYSA-N 0.000 description 2
- GKNDQVPUVLAVKE-UHFFFAOYSA-N 6-(4-benzylpiperazin-1-yl)-10-chlorothiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1N(CC1)CCN1CC1=CC=CC=C1 GKNDQVPUVLAVKE-UHFFFAOYSA-N 0.000 description 2
- KGPRCGOOUFUAGT-UHFFFAOYSA-N 6-(4-benzylpiperidin-1-yl)-10-chlorothiochromeno[2,3-c]quinolin-12-one Chemical compound N1=C2C=CC=CC2=C2C(=O)C3=CC(Cl)=CC=C3SC2=C1N(CC1)CCC1CC1=CC=CC=C1 KGPRCGOOUFUAGT-UHFFFAOYSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- QYHIFOUZVBWMSQ-UHFFFAOYSA-N 10-chloro-6-(4-hydroxypiperidin-1-yl)thiochromeno[2,3-c]quinolin-12-one Chemical compound C1CC(O)CCN1C1=NC2=CC=CC=C2C2=C1SC1=CC=C(Cl)C=C1C2=O QYHIFOUZVBWMSQ-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- 101710128979 23 kDa piroplasm membrane protein Proteins 0.000 description 1
- CLASNDUGDDUNQY-UHFFFAOYSA-N 3-(4-chlorophenyl)sulfanyl-2-oxo-1h-quinoline-4-carboxylic acid Chemical compound O=C1NC2=CC=CC=C2C(C(=O)O)=C1SC1=CC=C(Cl)C=C1 CLASNDUGDDUNQY-UHFFFAOYSA-N 0.000 description 1
- JTSFIVQMXUDGAB-UHFFFAOYSA-N 4-thiomorpholin-4-ylmorpholine Chemical compound C1COCCN1N1CCSCC1 JTSFIVQMXUDGAB-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 101710094326 Ras-related protein R-Ras Proteins 0.000 description 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101710157927 Translationally-controlled tumor protein Proteins 0.000 description 1
- 101710175870 Translationally-controlled tumor protein homolog Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 101150115114 dnaJ gene Proteins 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 102000029724 enzyme binding proteins Human genes 0.000 description 1
- 108091009282 enzyme binding proteins Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明公开了一系列新颖脱氢硫胺[2,3‑c]喹啉‑12‑酮衍生物，并进一步提供该些衍生物的制备方法及其应用，该应用包含将该类衍生物作为治疗癌症的医药组合物，且其应用包含该类衍生物具有明显抑制癌细胞生长的能力、抑制第一、二型拓朴异构酶的活性，进而治疗癌症等功效。
Description
技术领域
本发明涉及癌症药物技术领域，特别涉及脱氢硫胺[2,3-c]喹啉-12-酮衍生物、其抗癌活性应用及评估。
背景技术
在大多数的生物体中，端粒长度的复制与维持，必须依赖端粒酶 (telomerase)。端粒酶为一种核糖核酸蛋白酶，是由RNA与蛋白质次单元组成的复合体。目前，部分重要的端粒酶次单元已被鉴定出来，就人类端粒酶组成而言，包括具反转录酶活性的人类的端粒酶反转录酶(human telomerase reverse transcriptase,hTERT)，以及作为模板的人类端粒酶RNA组成体(human telomerase RNA component)，和一些与端粒酶结合的蛋白如：人类端粒酶结合蛋白(human telomerase-associated protein)、p23、hsp90、hsp40、hsp70等。
许多研究指出，人类端粒酶活性仅存在一些具高度增生能力的细胞中，例如：生殖细胞(germ cell)、造血细胞、部分干细胞(stem cell)、大部分的不死细胞(immortalizedcell)及绝大部分的肿瘤细胞。在一般体细胞中，由于不含有端粒酶活性，因此端粒会随细胞分裂次数的增加而逐渐减短，这可视为细胞计算分裂次数的指标(mitotic clock)。而当端粒短至一定程度时，细胞会停止分裂而进入老化阶段，且细胞会在此阶段停留一段时间，而后走向死亡，此时期称之为M1期(mortality stage 1)；若于M1期，细胞内的抑制肿瘤基因(tumor suppressor gene)发生突变，如p53和Rb，会促使细胞逃离老化阶段而继续进行细胞分裂，此时期称之为M2期(mortality stage 2)。此时期因不具端粒酶活性的存在，因此端粒长度仍会缩短，而此时端粒无法保护染色体末端的完整性，进而导致染色体不稳定现象产生，细胞无法完整的将遗传讯息传递而逐渐死亡，因此M2期又称之为危机期(crisis)；大部分的细胞会于M2期死亡，仅有少数细胞会因端粒酶活性的表达而存活，此细胞可不受限制的持续性分裂，成为不死细胞(或癌细胞)。
因此一般认为：活化端粒酶，可维持端粒长度而避免细胞进入复制性衰老，或将端粒酶活性去除，抑制其活性，以限制癌细胞的分裂，两者可为细胞朝向不老及癌化发展的关键。综合上述，由于正常人类体细胞不具有端粒酶活性，因此，一个能够抑制端粒酶活性的药物，在对端粒酶产生抑制作用时，对正常细胞的生理状况并不会产生影响，相反地，此活性抑制药物却能减弱癌细胞的增生能力，所以若能找寻到端粒酶活性抑制剂，通过抗癌机转的探讨，朝癌症治疗药物发展是深具潜力的。
癌症起因是由于DNA的异常增殖。因此，只要可以选择性地攻击癌细胞的 DNA即可，不希望伤害到正常细胞的DNA，但要分辨正常细胞的DNA和癌细胞的DNA是很困难的，于是在发现正常细胞和癌细胞之间特性的差别后，便产了具有专一性的「标靶治疗」，此治疗结合其它化学疗法或是放射疗法时，能够大幅降低副作用而达到更好的疗效，故标靶治疗是现今热门的研究治疗癌症的方向。因为拓朴异构酶(topoisomerase)在DNA的复制过程中扮演不可或缺的角色，故为近年抗癌标靶治疗研究中的标的。
喜树碱是第一个小分子药物用于抑制第一型拓朴异构酶，可惜的是喜树碱有许多缺点导致无法于临床医疗上使用，例如内酯环(lactone ring)在人体内pH 值环境下易水解变成羟基羧酸(hydroxycarboxylate)，导致易和体内血清白蛋白结合而失去药物抑制第一型拓朴异构酶的作用；camptothecin-Top I-DNA的三复合体因非以共价键连接故结构不稳定；喜树碱的水溶性不佳，导致生体可用率 (bioavailability)不佳；细胞膜上的p-glycoprotein(MDR1,ABCB1)排出帮浦将药物推出至细胞外；更重要的是一些肿瘤细胞渐渐对喜树碱及其衍生物产生抗药性及不良的药物副作用，使得即使之后上市较喜树碱增加了许多水溶性的两个经由半合成(semi-synthetic)的药物，在公元1996年由美国食品药物管理局(FDA) 核准于治疗卵巢癌的Topotecan及治疗结肠癌的Irinotecan面临临床治疗上的困境。因此，拓朴异构酶活性抑制剂于癌症治疗药物发展上是非常重要的。
发明内容
基于此，本发明的目的在于提供一种脱氢硫胺[2,3-c]喹啉-12-酮衍生物。
解决上述技术问题的具体技术方案如下：
一种式(I)化合物，
其中R是选自下列取代基所组成的群组：
i)卤基、胺基、羟基及硫基；
ii)NH(CH2)nH的直链烷基、带有支链取代的烷基、具有一胺基取代的烷基支链、具有一羟基取代的烷基支链，其中1≤n≤10；
iii)O(CH2)nH、N(CH3)2、NH(CH2)nNH(CH2)nOH；其中1≤n≤10；
iv)C3-12含氮的环烷基及杂环基团，它含有从1至3个选自于O、S以及N 的杂原子，其中邻位、间位或对位更可独立地选自下列取代基其中之一：氢基、(CH2)n烷基、(CH2)n羟基、(CH2)nC3-12环烷基、(CH2)nC3-12含氮环烷基、(CH2)n苯环、醛基及(CH2)nCOC3-12含氮环烷基；其中0≤n≤10；
v)NH(CH2)nR1，0≤n≤10，R1是选自下列取代基其中之一：N(CH3)2， C(NH2)2，NH(CH2)nH的直链烷基、带有支链取代的烷基、具有一胺基取代的烷基支链、具有一羟基取代的烷基支链；
vi)NH(CH2)nR2，0≤n≤10，R2是选自下列取代基其中之一：苯环、C3-12环烷基及杂环基团，含有从1至3个选自于O、S以及N的杂原子，其中邻位、间位或对位更可独立地选自下列取代基其中之一：甲氧基、胺基、苯环、带有C1-C3支链取代的烷基、胺基、硝基、羟基及C3-12杂环；其中该C3-12杂环含有从1至3个选自于O、S以及N的杂原子；以及医药上可接受的盐、立体异构物及镜像异构物。
为达成前述发明目的，其中取代基群组i)-vi)是选自由氯、羟基、甲氧基、二甲氨基、哌嗪-1-基、4-甲基哌嗪-1-基、4-乙基哌嗪-1-基、4-(2-羟乙基)哌嗪-1- 基、4-芐基哌嗪-1-基、4-苯基哌嗪-1-基、吗啉代、硫代吗啉代、哌啶-1-基、4- 羟基哌啶-1-基、4-芐基哌啶-1-基、[1,4'-联哌啶]-1'-基、4-(3-(哌啶-4-基)丙基、吡咯烷-1-基、2-氧代哌啶-1-基、甲基氨基、乙基氨基、丙基氨基、丁基氨基、异丁基、戊-3-基氨基、(2-(二甲基氨基)乙基)氨基、(2-(二乙基氨基)乙基)氨基、2- 乙醇氨基、3-丙醇氨基、5-戊醇氨基、(1-羟基丁烷-2-基)氨基、(4-甲基戊-2-基) 氨基、(2-氨基乙基)氨基、(2-((2-羟乙基)氨基)乙基)氨基、(2-吗啉代乙基)氨基、 (3-(二甲基氨基)丙基)氨基、(3-(二乙氨基)丙基)氨基、(3-((2-羟乙基)氨基)丙基) 氨基、(2,3-二氢-1H-茚-2-基)氨基、环己基、(1-芐基哌啶-4-基)氨基、(噻吩-2-基甲基)氨基、(环己基甲基)氨基、芐基氨基、(吡啶-2-基甲基)氨基、(苯并[d][1,3] 二氧杂环戊烯-5-基甲基)氨基、(2-甲氧芐基)氨基、(3,4-二甲氧基芐基)氨基、苯乙基氨基、(4-甲氧基苯乙基)氨基、(4-氨基苯乙基)氨基、胍及哌啶-1-基氨基所组成的群组。
为达成前述发明目的，其中该化合物是选自由下列所组成的群组：化合物 2-21及N1-N34。
3-((4-氯苯基)硫代)-2-羟基喹啉-4-羧酸、
6,9-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮、
10-氯-6-羟基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-甲氧基-12H-脱氢硫*胺并[2,3-c]喹啉-12-酮、
10-氯-6-二甲氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-甲基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-乙基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-(2-羟乙基)哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉12-酮、
6-(4-芐基哌嗪-1-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-苯基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-吗啉代-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-硫代吗啉代-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-羟基哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(4-芐基哌啶-1-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-([1,4'-联哌啶]-1'-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-(3-(哌啶-4-基)丙基)哌啶-1-基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(吡咯烷-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(2-氧代哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-甲基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-乙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-丙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(丁基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-异丁基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(戊-3-基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二甲基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二乙基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(2-乙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(3-丙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(5-戊醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((1-羟基丁烷-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((4-甲基戊-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((2-氨基乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-((2-羟乙基)氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-吗啉代乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二甲基氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二乙氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-((2-羟乙基)氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2,3-二氢-1H-茚-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(环己基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((1-芐基哌啶-4-基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((噻吩-2-基甲基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((环己基甲基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(芐基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((吡啶-2-基甲基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((苯并[d][1,3]二氧杂环戊烯-5-基甲基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]
喹啉-12-酮、
10-氯-6-((2-甲氧芐基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3,4-二甲氧基芐基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(苯乙基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((4-甲氧基苯乙基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((4-氨基苯乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
2-(10-氯-12-氧代-12H-脱氢硫胺并[2,3-c]喹啉-6-基)胍、
10-氯-6-(哌啶-1-基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
以及其等的盐类。
本发明的另一目的在于提供一种医药组合物，包含治疗有效量的如前述的化合物，和至少一种医药上可接受载剂、稀释剂或赋形剂。
本发明的另一目的在于提供一种如前述的化合物的用途，其是用于制造可用于抑制第一型拓朴异构酶活性的医药品。
本发明的另一目的在于提供一种如前述的化合物的用途，其是用于制造可用于抑制第二型拓朴异构酶活性的医药品。
本发明的另一目的在于提供一种如前述的化合物的用途，其是用于制造可用于治疗癌症的医药品。
为达成前述发明目的，其中该癌症是选自白血病、非小细胞肺癌、大肠癌、中枢神经癌、黑色素瘤、卵巢癌、肾脏癌、前列腺癌及乳癌所组成。
本发明的另一目的是在于提供一种制造上述化合物的方法，该方法包含：
(1)将isatin、2-((4-chlorophenyl)thio)acetic acid及醋酸钠混合，于150℃反应1小时，将反应完的混合液冷却后加入醋酸得到沉淀物，再以醋酸、水、正己烷冲洗，得到化合物2(3-((4-氯苯基)硫代)-2-羟基喹啉-4-羧酸)；
(2)取化合物2(3-((4-氯苯基)硫代)-2-羟基喹啉-4-羧酸)溶于三氯氧磷150℃、48小时，冷却后将反应物倒入水中，过滤收集沉淀物置入10％碳酸氢钠溶液搅拌1小时，收集沉淀物后再以水冲洗，粗产物以二氯甲烷再结晶，得到化合物3 (6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮)；
(3)取化合物3(6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮)溶于DMF，加入浓盐酸并回流六小时，之后逐滴加入浓盐酸并再回流12小时，反应物以真空脱水，再加入水，过滤后粗产物以乙醇清洗得到化合物4(10-氯-6-羟基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮)；
(4)于甲醇中的悬浮化合物3(6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮)与甲醇钠回流16小时，冷却后移除溶剂，过滤后再以乙醇与正己烷清洗，得到化合物5(10-氯-6-甲氧基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮)；
(5)取化合物3(6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮)与一适当二级胺与碳酸钠溶于DMSO或DMF，回流10小时，静置冷却后，反应物加入冰水中，过滤出沉淀物后，以水及甲醇清洗收集分别得到化合物6-21：
10-氯-6-二甲氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-甲基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-乙基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-(2-羟乙基)哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉12-酮、
6-(4-芐基哌嗪-1-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-苯基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-吗啉代-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-硫代吗啉代-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-羟基哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(4-芐基哌啶-1-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-([1,4'-联哌啶]-1'-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(4-(3-(哌啶-4-基)丙基)哌啶-1-基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(吡咯烷-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、及
10-氯-6-(2-氧代哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮；
(6)取化合物3(6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮)与一适当一级胺溶于DMSO，回流8小时，冷却后，反应物加入100mL水中。过滤出沉淀物后，以水及甲醇清洗收集分别得到化合物N1-N34：
10-氯-6-甲基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-乙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-丙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(丁基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-异丁基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(戊-3-基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二甲基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二乙基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(2-乙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(3-丙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(5-戊醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((1-羟基丁烷-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((4-甲基戊-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((2-氨基乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-((2-羟乙基)氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-吗啉代乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二甲基氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二乙氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-((2-羟乙基)氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2,3-二氢-1H-茚-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(环己基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((1-芐基哌啶-4-基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((噻吩-2-基甲基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((环己基甲基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(芐基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((吡啶-2-基甲基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((苯并[d][1,3]二氧杂环戊烯-5-基甲基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c] 喹啉-12-酮、
10-氯-6-((2-甲氧芐基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3,4-二甲氧基芐基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(苯乙基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((4-甲氧基苯乙基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((4-氨基苯乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
2-(10-氯-12-氧代-12H-脱氢硫胺并[2,3-c]喹啉-6-基)胍、及
10-氯-6-(哌啶-1-基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮。
本发明所述的脱氢硫胺[2,3-c]喹啉-12-酮衍生物及其制备方法和应用具有以下优点和有益效果：
本发明所述脱氢硫胺[2,3-c]喹啉-12-酮衍生物具有明显抑制癌细胞生长的能力、抑制第一、二型拓朴异构酶的活性，进而治疗癌症等功效。
附图说明
图1为脱氢硫胺[2,3-c]喹啉-12-酮衍生物化学合成的反应概要；
图2为化合物5、7、8、16、19与CPT(喜树碱)于25、50μM，对于作用于第一型拓朴异构酶(TOP I)DNA解螺旋的效果；
图3为化合物N2、N7、N8、N9、N14-N19、N25与CPT于50μM，对于作用于第一型拓朴异构酶(TOP I)DNA解螺旋的效果；
图4a-d为化合物7、N7、N14、N15、N18、N19、N25与CPT于1-50μM，对于作用于第一型拓朴异构酶(TOP I)DNA解螺旋的效果；
图5为化合物5、7、8、16、19与VP-16(etoposide医百幸，作为正向对照组)于25、50μM，对于作用于第二型拓朴异构酶(TOP II)DNA解螺旋的效果；
图6为化合物N2、N7、N8、N9、N14-N19、N25与VP-16于50μM，对于作用于第二型拓朴异构酶(TOP II)DNA解螺旋的效果；
图7a-d为化合物7、N7、N8、N14、N15、N18、N19、N25与VP-16于1-50μM，对于作用于第二型拓朴异构酶(TOP II)DNA解螺旋的效果。
具体实施方式
本说明书中所述的所有技术性及科学术语，除非另外有所定义，皆为该所属领域具有通常技艺者可共同了解的意义。
术语“治疗”、“治疗中”及其类术语是指延缓、改善、减少或逆转目前正折磨着患者的该病症或该病症相关的任何症状的方法以及预防该病症或其任何正出现的症状的方法。
术语“药学上可接受”是指物质或组合物必须与调配物的其它成份兼容，且对患者无害。
本发明的组合物是可利用熟习此技艺者所详知的技术，将上述的乳杆菌分离株，与药学上可接受的载剂(pharmaceutically acceptable vehicle)，制备成适用本发明组合物的剂型。其中该剂形包含但不限于：溶液(solution)、乳剂(emulsion)、悬浮液(suspension)、粉末(powder)、锭剂(tablet)、丸剂(pill)、口含锭(lozenge)、片剂(troche)、口嚼胶(chewing gum)、胶囊(slurry)以及其它类似或适用本发明的剂型。
其中该药学上可接受的载剂可包含或多种选自于下列的试剂：溶剂(solvent)、乳化剂(emulsifier)、悬浮剂(suspending agent)、分解剂(decomposer)、黏结剂(bindingagent)、赋形剂(excipient)、安定剂(stabilizing agent)、螯合剂 (chelating agent)、稀释剂(diluent)、胶凝剂(gelling agent)、防腐剂(preservative)、润滑剂(lubricant)、表面活性剂(surfactant)，及其它类似或适用本发明的载剂。
上述组合物中，亦可视需要适宜地添加或多种以上制剂领域内通常使用的溶解补助剂、缓冲剂、保存剂、着色剂、香料、风味剂等。
术语“药学上可接受的赋形剂”，包括但不限于，聚合物、树脂、增塑剂、填料、润滑剂、稀释剂、黏合剂、崩解剂、溶剂、共溶剂、界面活性剂、防腐剂、甜味剂、调味剂、药学级的染料或颜料、及黏度剂至少一种。
术语“医药组成物(pharmaceutical composition)”为一种固体或液体组成物，其形式、浓度和纯度程度适合投予给病患(如人类或动物病患)，在投予之后，其可诱发所欲生理变化。医药组成物典型地为无菌及/或非发热性者(non-pyrogenic)。
本发明是以下面的实施例予以示范阐明，但本发明不受下述实施例所限制。本发明所用的药物、生物材料皆市售易于取得，下列仅为示例可取得的渠道。
所有反应通过涂有硅胶60F254的薄层色谱(TLC)监视。所有合成化合物的熔点是由Büchi B-545测定装置所测定。1H NMR：Varian GEMINI-300(300MHz) 或Agilent 400MRDD2(400MHz)；δ值单位为ppm，相对于四甲基硅烷(TMS) 作为内部标准(0ppm)。Multiplicities记为s(singlet),d(doublet),t(triplet),q (quartet),quin(quintuplet),sext(sextet),sep(septet),m(multiplet),dd(doublet of doublet),dt(doublet of triplet),td(triplet of doublet),qd(quartet of doublet)与br(broadened)。High resolution electrospray ionization(HRESI):Finnigan MAT 95S(仪器中心，国立台湾大学)。X-射线单晶衍射：Bruker Enraf-Nonius APEX IIdiffractometer(国立台湾师范大学化学系)。典型的实验中指出用于thiochromenoquinolones制备的一般程序，描述如下(图1)。
化学合成步骤通则
合成步骤通则A：合成化合物2。
将isatin(0.44g，2.99mmole)及2-((4-chlorophenyl)thio)acetic acid(0.70g,3.47mmol)及sodium acetate(0.05g)混合，于miniclave(150℃)反应1小时 (thin-layerchromatography，TLC监控)。将反应完的混合液冷却后加入acetic acid(10mL)得到灰色沉淀物，醋酸、水、正己烷冲洗，可得到亮紫色化合物。
合成步骤通则B：合成化合物3。
取化合物2溶于三氯氧磷(5mL)150℃48小时。冷却后将反应物倒入0℃冰水，过滤收集绿色沉淀物置入10％碳酸氢钠溶液(50mL)剧烈搅拌1小时，收集沉淀物后再以水冲洗。粗产物以二氯甲烷再结晶，得到黄色产物化合物3。
合成步骤通则C：合成化合物4。
取化合物3(0.32g,0.96mmol)溶于DMF(20mL)，加入浓盐酸(3mL)并回流(refluxed)。六小时后，逐滴加入浓盐酸(6mL)并再回流12小时。反应物以真空脱水，再加入水20mL，过滤后粗产物以乙醇清洗得到黄色固体化合物4。
合成步骤通则D：合成化合物5。
于20mL甲醇中的悬浮化合物3(0.33g,1.0mmol)与甲醇钠(0.55g,10mmol) 回流16小时。冷却后以旋转蒸发真空仪器移除溶剂，过滤后再以乙醇与正己烷清洗，得到白色固体化合物5。
合成步骤通则E：合成化合物6-21。
取化合物3(0.33g,1.0mmol)与一适当二级胺(1.1mmol)与碳酸钠(5mmol) 溶于DMSO或DMF(20mL)，回流10小时(TLC监控)。静置冷却后，反应物加入100mL冰水中。过滤出沉淀物后，以水及甲醇清洗收集得到黄色固体。
合成步骤通则F：合成化合物N1-34。
取化合物3(0.33g,1.0mmol)与一适当一级胺(1.1mmol)溶于DMSO(30 mL)，回流8小时(TLC监控)。冷却后，反应物加入100mL水中。过滤出沉淀物后，以水及甲醇清洗收集得到黄色固体。
以下将结合具体实施例对本发明做进一步说明。
实施例1
3-((4-氯苯基)硫代)-2-羟基喹啉-4-羧酸(2)
3-((4-Chlorophenyl)thio)-2-hydroxyquinoline-4-carboxylic acid(TC-SCl)(2)
该纯化合物为灰色固体(产率86％)。(Rf＝0.5at EA:AcOH＝20:1).Mp 306-308℃.1H NMR(300MHz,DMSO-d6):δ(ppm)7.26(3H,t,J＝7.6Hz,Ar-H), 7.34(2H,d,J＝6.0Hz,Ar-H),7.39(1H,d,J＝8.0Hz,Ar-H),7.46(1H,d,J＝8.0 Hz,Ar-H),7.62(1H,t,J＝8.0Hz,Ar-H),12.22(1H,s,-COOH).13C NMR(100 MHz,DMSO-d6):δ(ppm)115.58,116.26,120.36,123.21,126.21,129.33,130.30, 131.47,132.54,134.36,140.11,151.69,159.37,166.80(CO).HRMS(ESI)calcd for C16H10NO3SCl[M]+331.0070；found[M+H]+332.0147(100),[M+H+2]+334.0122 (33)；found[M-H]-330.0002.
实施例2
6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮(3)
6,10-Dichloro-12H-thiochromeno[2,3-c]quinolin-12-one(3)
分离出黄色固体(产率90％)。(Rf＝0.50at CH2Cl2:n-hexane＝1:1).Mp 259-261℃(CH2Cl2).1H NMR(400MHz,CDCl3):δ(ppm)7.71(2H,m,Ar-H), 7.77-7.85(2H,m,Ar-H),8.10-8.13(m,1H,Ar-H),8.60(t,1H,J＝1.2Hz,Ar-H), 9.67-9.71(1H,m,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)124.87,126.28, 127.85,129.17,129.39,129.93,130.31,131.20,131.90,133.01,133.09,133.38, 134.43,145.27,146.61,180.64(CO).HRMS(ESI)calcd for C16H7NOSCl2[M]+ 330.9625；found[M+H]+331.9699(100),[M+H+2]+333.9672(67),[M+H+4]+ 335.9645(11).
实施例3
10-氯-6-羟基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(4)
10-Chloro-6-hydroxy-12H-thiochromeno[2,3-c]quinolin-12-one(4)
分离出黄色固体(产率95％)。(Rf＝0.40at EA).Mp>410℃.1H NMR(400 MHz,DMSO-d6):δppm 7.35(1H,td,J＝7.2,1.2Hz,Ar-H),7.47(1H,dd,J＝8.4, 1.2Hz,Ar-H),7.59(1H,td,J＝7.2Hz,1.6Hz,Ar-H),7.89(1H,dd,J＝8.4Hz,2.4 Hz,Ar-H),8.10(1H,d,J＝8.8Hz,Ar-H),8.38(1H,d,J＝2.4Hz,Ar-H),9.35(1H, dd,J＝8.4,2.4Hz,Ar-H),12.73(br,1H,-OH).13C NMR(75MHz,CDCl3):δ(ppm) 116.61,117.52,123.65,126.82,128.44,130.22,130.49,130.54,132.52,133.00, 133.42,135.09,136.27,138.90,158.70,180.38(CO).HRMS(ESI)m/z calcd for C16H8NO2SCl[M]+:312.9964,found,314.0051.
实施例4
10-氯-6-甲氧基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(5)
10-Chloro-6-methoxy-12H-thiochromeno[2,3-c]quinolin-12-one(5)
分离出灰色固体(产率91％)。(Rf＝0.52at CH2Cl2:n-hexane＝1:1).Mp 227-228℃.1H NMR(400MHz,CDCl3):δ(ppm)4.27(3H,s,-OCH3),7.60(1H,td, J＝7.6,1.2Hz,Ar-H),7.37(1H,d,J＝2.0Hz,Ar-H),7.70(1H,td,J＝7.6Hz,1.6 Hz,Ar-H),7.94(1H,dd,J＝8.0Hz,1.2Hz,Ar-H),8.60(1H,d,J＝1.6Hz,Ar-H), 9.64(1H,dd,J＝8.8Hz,1.2Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)54.83 (OCH3),122.91,126.23,126.54,126.76,127.66,127.95,129.23,129.50,130.54, 132.49,133.48,133.85,143.82,156.06,180.47(CO).HRMS(ESI)m/z calcd for C17H10NO2SCl[M]+327.0121；found[M+H]+328.0203,[M+H+2]+330.0172.
实施例5
10-氯-6-二甲氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(6)
10-Chloro-6-dimethylamino-12H-thiochromeno[2,3-c]quinolin-12-one(6)
分离出黄色固体(产率85％)。(Rf＝0.45at CH2Cl2:n-hexane＝1:1).Mp 194-195℃.1H NMR(400MHz,CDCl3):δ(ppm)3.06(6H,s,-CH3),7.59-7.67(3H, m,Ar-H),7.71(1H,t,J＝7.2Hz,Ar-H),8.00(1H,d,J＝8.4Hz,Ar-H),8.59(1H,d, J＝1.2Hz,Ar-H),9.60(1H,d,J＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ (ppm)43.00,123.44,125.71,127.22,127.78128.47,129.07,129.37,130.59,130.67, 132.23,132.46,133.61,134.36,144.84,158.32,181.52(CO).HRMS(ESI)calcd for C18H13N2OSCl[M]+340.0437；found[M+H]+341.0517(100),[M+H+2]+343.0501 (33).
实施例6
10-氯-6-(哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(7)
10-Chloro-6-(piperazin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-one(7)
分离出黄色固体(产率69％)。(Rf＝0.12at EA:MeOH:ammonia water＝20:5: 1).Mp 211-213℃.1H NMR(400MHz,CDCl3):δ(ppm)3.20(4H,t,J＝4.8Hz, -CH2-),3.36(4H,t,J＝4.8Hz,-CH2-),7.60-7.66(3H,m,Ar-H),7.70(1H,td,J＝8.0, 1.2Hz,Ar-H),7.99(1H,dd,J＝8.4,0.8Hz,Ar-H),8.56(1H,d,J＝2.0Hz,Ar-H), 9.60(1H,dd,J＝8.4,0.8Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)45.95, 52.31,123.62,125.81,127.58,127.86,128.72,129.10,129.37,130.65,130.99, 132.17,132.47,133.63,134.33,144.94,157.61,181.45(CO).HRMS(ESI)calcd for C20H16N3OSCl[M]+381.0703；found[M+H]+382.0783.
实施例7
10-氯-6-(4-甲基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(8)
10-Chloro-6-(4-methylpiperazin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-one (8)
分离出黄绿色固体(产率80％)。(Rf＝0.24at EA:methanol＝5:1).Mp 212-214℃.1H NMR(400MHz,CDCl3):δ(ppm)2.51(3H,s,-CH3),2.84(4H,br,-CH2-), 3.50(4H,t,J＝4.5Hz,-CH2-),7.60-7.66(3H,m,Ar-H),7.68-7.72(1H,td,J＝8.1, 1.5Hz,Ar-H),8.01(1H,dd,J＝8.1,1.5Hz,Ar-H),8.56(1H,d,J＝1.5Hz,Ar-H), 9.60(1H,dd,J＝8.4,1.5Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)45.73, 50.31,54.65,123.70,125.90,127.60,127.80,128.82,129.20,129.39,130.62,130.84, 132.36,132.47,133.78,134.24,145.08,157.18,181.42(CO).HRMS(ESI)calcd for C21H18N3OSCl[M]+395.0859；found[M+H]+396.0926.
实施例8
10-氯-6-(4-乙基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(9)
10-Chloro-6-(4-ethylpiperazin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-one (9)
分离出黄色固体(产率74％)。(Rf＝0.48at EA:MeOH＝10:1).Mp 196-198℃. 1HNMR(400MHz,CDCl3):δ(ppm)1.19(3H,t,J＝7.2Hz,-CH3),2.58(2H,q,J＝ 7.2Hz,-CH2-),2.78(4H,br,-CH2-),3.46(4H,t,J＝4.4Hz,-CH2-),7.61-7.66(3H, m,Ar-H),7.68-7.73(1H,td,J＝8.4,1.6Hz,Ar-H),8.01(1H,dd,J＝8.0,1.2Hz, Ar-H),8.59(1H,d,J＝4.0Hz,Ar-H),9.62(1H,dd,J＝8.4,0.8Hz,Ar-H).13C NMR (100MHz,CDCl3):δ(ppm)12.07,50.88,52.46,52.67,123.55,125.77,127.48, 127.83,128.78,129.12,129.36,130.62,130.76,132.21,132.47,133.62,134.34, 144.97,157.34,181.50(CO).HRMS(ESI)calcd forC22H20N3OSCl[M]+409.1016； found[M+H]+410.1069.
实施例9
10-氯-6-(4-(2-羟乙基)哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉12-酮(10)
10-Chloro-6-(4-(2-hydroxyethyl)piperazin-1-yl)-12H-thiochromeno[2,3-c]quino lin-12one(10)
分离出黄绿色固体(产率60％)。(Rf＝0.37at EA:MeOH＝2:1).Mp 211-213℃. 1HNMR(400MHz,CDCl3):δ(ppm)2.74(2H,t,J＝5.2Hz,-CH2-),2.87(4H,t,J＝ 3.6Hz,-CH2-),3.45(4H,t,J＝3.6Hz,-CH2-),3.72(2H,t,J＝5.2Hz,-CH2O-), 7.62-7.67(3H,m,Ar-H),7.72(1H,td,J＝7.2,1.6Hz,Ar-H),8.01(1H,dd,J＝8.4, 1.2Hz,Ar-H),8.59(1H,d,J＝0.6Hz,Ar-H),9.62(1H,dd,J＝4.8,1.2Hz,Ar-H). 13C NMR(100MHz,CDCl3):δ(ppm)50.85,52.72,57.74,59.35,123.65,125.81, 127.66,127.82,128.73,129.14,129.44,130.68,130.77,132.19,132.51,133.69, 134.21,144.90,157.26,181.43(CO).HRMS(ESI)calcdfor C22H20N3O2SCl[M]+ 425.0965；found[M+H]+426.1024.
实施例10
6-(4-芐基哌嗪-1-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(11)
6-(4-Benzylpiperazin-1-yl)-10-chloro-12H-thiochromeno[2,3-c]quinolin-12-one (11)
分离出黄色固体(产率81％)。(Rf＝0.43at EA:n-hexane＝1:4).Mp 191-193 ℃.1H NMR(400MHz,CDCl3):δ(ppm)2.78(4H,br,-CH2N-),3.43(4H,t,J＝4.85 Hz,-NCH2-),3.68(2H,s,-CH2-),7.27-7.42(5H,m,Ar’-H),7.61-7.67(3H,m, Ar-H),7.71(1H,td,J＝7.6,1.6Hz,Ar-H),8.00(1H,dd,J＝8.4,1.2Hz,Ar-H),8.58 (1H,d,J＝2.0Hz,Ar-H),9.61(1H,dd,J＝8.4,1.2Hz,Ar-H).13C NMR(100MHz, CDCl3):δ(ppm)50.94,52.96,63.08,123.57,125.78,127.18,127.48,127.83,128.33, 128.73,129.09,129.17,129.34,130.58,130.90,132.18,132.44,133.60,134.36, 138.11,144.95,157.48,181.47(CO).HRMS(ESI)calcd for C27H22N3OSCl[M]+ 471.1172；found[M+H]+472.1241.
实施例11
10-氯-6-(4-苯基哌嗪-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(12)
10-Chloro-6-(4-phenylpiperazin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-one (12)
分离出黄色固体(产率77％)。(Rf＝0.73at EA:n-hexane＝1:4).Mp 236-237 ℃.1H NMR(300MHz,CDCl3):δ(ppm)3.50-3.60(8H,m,-CH2-),6.94(1H,t,J＝7.2Hz,Ar’-H),7.04(2H,d,J＝8.4Hz,Ar’-H),7.33(2H,t,J＝7.5Hz,Ar’-H), 7.63-7.67(3H,m,Ar-H),7.71(1H,t,J＝7.2Hz,Ar-H),8.02(1H,d,J＝7.2Hz, Ar-H),8.58(1H,s,Ar-H),9.63(1H,d,J＝8.1Hz,Ar-H).13C NMR(75MHz, CDCl3):δ(ppm)48.60,50.33,115.77,119.51,123.21,125.38,127.14,127.30,128.27, 128.65,128.71,128.88,130.23,131.77,131.97,133.22,133.70,144.52,150.90, 156.83,159.91,180.91(CO).HRMS(ESI)calcd forC26H20N3OSCl[M]+457.1016； found[M+H]+458.1095.
实施例12
10-氯-6-吗啉代-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(13)
10-Chloro-6-morpholino-12H-thiochromeno[2,3-c]quinolin-12-one(13)
分离出黄色固体(产率70％)。(Rf＝0.42at CH2Cl2).Mp 217-218℃.1H NMR(300MHz,CDCl3):δ(ppm)3.41(4H,t,J＝4.5Hz,-NCH2-),4.02(4H,t,J＝4.5Hz, -CH2O-),7.62-7.70(3H,m,Ar-H),7.73(1H,td,J＝7.5,1.5Hz,Ar-H),8.03(1H,dd, J＝8.4,1.5Hz,Ar-H),8.59(1H,dd,J＝2.1,0.6Hz,Ar-H),9.35(1H,dd,J＝8.7,1.8 Hz,Ar-H).13C NMR(75MHz,CDCl3):δ(ppm)51.36,66.88,123.92,126.06, 127.85,127.91,128.94,129.34,129.52,130.71,131.05,132.50,132.61,133.95, 134.29,145.23,157.29,181.51(CO).HRMS(ESI)calcd for C20H15N2O2SCl[M]+ 382.8633；found[M+H]+383.0620.
实施例13
10-氯-6-硫代吗啉代-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(14)
10-Chloro-6-thiomorpholino-12H-thiochromeno[2,3-c]quinolin-12-one(14)
分离出黄色固体(产率86％)。(Rf＝0.77at EA:n-hexane＝1:4).Mp 219-220 ℃.1H NMR(300MHz,CDCl3):δ(ppm)2.98(4H,t,J＝4.8Hz,-NCH2-),3.64(4H, t,J＝5.1Hz,-SCH2-),7.62-7.84(3H,m,Ar-H),7.73(1H,td,J＝8.4,1.8Hz,Ar-H), 8.06(1H,dd,J＝8.1,1.5Hz,Ar-H),8.57(1H,dd,J＝1.8,0.6Hz,Ar-H),9.61(1H, dd,J＝7.8,1.2Hz,Ar-H).13CNMR(75MHz,CDCl3):δ(ppm)27.06,52.64,114.95, 123.23,125.40,127.27,127.31,128.30,128.68,128.87,130.55,131.81,131.96, 133.29,133.70,144.93,157.43,180.86(CO).HRMS(ESI)m/z calcd for C20H15N2S2OCl+[M]+398.0314,found[M+H]+399.0420,[M+H+2]+401.0394.
实施例14
10-氯-6-(哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(15)
10-Chloro-6-(piperidin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-one(15)
分离出黄色固体(产率86％)。(Rf＝0.75at EA).Mp 187-188℃.1H NMR(400 MHz,CDCl3):δ(ppm)1.71-1.74(2H,m,-CH2-),1.88(4H,p,J＝4.5Hz,-CH2-), 3.31(4H,t,J＝4.2Hz,-NCH2-),7.60-7.64(2H,m,Ar-H),7.61(1H,d,J＝6.3Hz, Ar-H),7.69(1H,td,J＝5.1,1.2Hz,Ar-H),7.99(1H,dd,J＝5.4,0.6Hz,Ar-H),8.58 (1H,d,J＝1.5Hz,Ar-H),9.62(1H,dd,J＝6.3,0.6Hz,Ar-H)13C NMR(100MHz, CDCl3):δ(ppm)24.27,25.89,52.33,123.47,125.75,127.28,127.85,128.56,129.02, 129.23,130.48,131.62,132.16,132.33,133.46,134.67,144.97,158.50,181.51(CO). HRMS(ESI)calcd for C21H17N2OSCl[M]+380.0750；found[M+H]+381.0816.
实施例15
10-氯-6-(4-羟基哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(16)
10-Chloro-6-(4-hydroxypiperidin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-on e(16)
分离出黄灰色固体(产率84％)。(Rf＝0.4at EA:n-hexane＝1:1).Mp 224-225℃.1H NMR(400MHz,CDCl3):δ(ppm)1.89(1H,td,J＝7.2,2.7Hz, piperidine-CHa),1.94(1H,td,J＝6.9,2.7Hz,piperidine-CHa),2.15-2.21(2H,m, piperidine-CHe),3.19(2H,td,J＝8.4,2.1Hz,piperidine-NCHa),3.60-3.65(2H,m, piperidine-NCHe),4.01(1H,sext,J＝3.0Hz,piperidine-CH),7.61-7.67(3H,m, Ar-H),7.71(1H,td,J＝6.3,1.2Hz,Ar-H),7.99(1H,dd,J＝6.3,0.6Hz,Ar-H),8.59 (1H,dd,J＝1.5,0.6Hz,Ar-H),9.64(1H,dd,J＝6.3,0.6Hz,Ar-H).13C NMR(100 MHz,CDCl3):δ(ppm)34.49,48.90,67.80,123.62,125.82,127.54,127.88,128.64, 129.11,129.36,130.61,131.29,132.20,132.47,133.63,134.43,144.91,157.83, 181.47(CO).HRMS(ESI)calcd for C21H17N2OSCl[M]+396.0699；found[M+H]+ 397.0757.
实施例16
6-(4-芐基哌啶-1-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(17)
6-(4-Benzylpiperidin-1-yl)-10-chloro-12H-thiochromeno[2,3-c]quinolin-12-one (17)
分离出黄色固体(产率90％)。(Rf＝0.57at CH2Cl2:n-hexane＝2:1).Mp 184-185℃.1H NMR(400MHz,CDCl3):δ(ppm)1.67(2H,td,J＝9.3,3.0Hz, -CH2-),1.79-1.89(1H,m,-CH-),1.88(2H,d,J＝6.9Hz,piperidine-CH2),2.71(2H, d,J＝5.1Hz,piperidine-CH2),3.00(2H,td,J＝9.3,1.2Hz,-NCH2-),3.65(2H,d,J ＝9.3Hz,-NCH2-),7.20-7.25(3H,m,Ar-H),7.31-7.33(2H,m,Ar-H),7.60-7.72(4H, m,Ar-H),7.98(1H,dd,J＝6.3,0.6Hz,Ar-H),8.59(1H,d,J＝1.8Hz,Ar-H),9.62 (1H,dd,J＝6.6,0.6Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)32.21,37.88, 43.30,51.64,123.52,125.79,125.99,127.36,127.87,128.61,129.09,129.17,129.29, 130.55,131.49,132.22,132.41,133.54,134.62,140.46,144.98,147.04,158.25, 181.55(CO).HRMS(ESI)calcd for C28H23N2OSCl[M]+471.0130；found[M+H]+ 471.1276.
实施例17
6-([1,4'-联哌啶]-1'-基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(18)
6-([1,4'-Bipiperidin]-1'-yl)-10-chloro-12H-thiochromeno[2,3-c]quinolin-12-one (18)
分离出黄色固体(产率92％)。(Rf＝0.15at EA:MeOH＝5:1).Mp 187-189℃. 1HNMR(400MHz,CDCl3):δ(ppm)1.50-1.52(2H,m,piperidine-H),1.66-1.67(3H, m,piperidine-H),1.86-1.98(2H,qd,J＝12.4,2.8Hz,piperidine-H),2.06(2H,d,J＝11.6Hz,piperidine-H),2.54(1H,t,J＝10.8Hz,piperidine-H),2.65(3H,br,piperidine-H),3.05(2H,t,J＝12Hz,piperidine-H),3.73(2H,d,J＝12.8Hz,piperidine-H),7.60-7.66(3H,m,Ar-H),7.70(1H,td,J＝8.0,1.2Hz,Ar-H),7.98 (1H,d,J＝8.0Hz,Ar-H),8.58(1H,s,Ar-H),9.62(1H,d,J＝8.8Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)24.79,26.36,28.24,50.45,51.16,62.40,123.57, 125.80,127.42,127.86,128.61,129.08,129.30,130.52,131.41,132.18,132.43, 133.56,134.54,144.92,157.92,181.47(CO).HRMS(ESI)calcd for C26H26N3OSCl [M]+463.1485；found[M+H]+464.1593.
实施例18
10-氯-6-(4-(3-(哌啶-4-基)丙基)哌啶-1-基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮 (19)
10-Chloro-6-(4-(3-(piperidin-4-yl)propyl)piperidin-1-yl)-12H-thiochromeno[2,3 -c]quinolin-12-one(19)
分离出黄色固体(产率76％)。(Rf＝0.13at CH2Cl2).Mp 164-165℃.1H NMR(400MHz,CDCl3):δ(ppm)1.16(2H,qd,J＝11.6,3.2Hz,-CH2-),1.20-1.28(2H,m, -CH2-),1.36-1.39(4H,m,-CH2-),1.51-1.58(4H,m,-CH2-),1.70(2H,d,J＝13.6Hz, -CH2-),1.87(2H,d,J＝9.6Hz,-CH2-),2.43(1H,br,-NH),2.60(2H,td,J＝12.0, 2.0Hz,-CH2-),2.99(2H,t,J＝11.2Hz,-CH2-),3.10(2H,d,J＝12Hz,-CH2-),3.64 (2H,d,J＝12.4Hz,-CH2-),7.59-7.65(3H,m,Ar-H),7.68(1H,td,J＝8.0,1.2Hz, Ar-H),8.00(1H,dd,J＝11.2,1.2Hz,Ar-H),8.57(1H,d,J＝1.6Hz,Ar-H),9.61(1H, d,J＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)23.66,32.40,33.24, 35.73,36.08,36.86,37.38,46.58,51.76,123.49,125.79,127.30,127.84,128.57, 129.05,129.26,130.49,131.55,132.17,132.36,133.50,134.64,144.98,158.34, 181.50(CO).HRMS(ESI)calcd for C29H32N3OSCl[M]+505.1955；found[M+H]+ 506.2004.
实施例19
10-氯-6-(吡咯烷-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(20)
10-Chloro-6-(pyrrolidin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-one(20)
分离出黄色固体(产率86％)。(Rf＝0.56at CH2Cl2:n-hexane＝1:1).Mp 170-171℃.1H NMR(300MHz,CDCl3):δ(ppm)2.05(4H,quin,J＝3.6Hz,-CH2-), 3.76(4H,t,J＝6.9Hz,-NCH2-),7.50(1H,td,J＝7.2,1.5Hz,Ar-H),7.61(1H,d,J＝ 1.5Hz,Ar-H11),7.65(1H,td,J＝7.5,1.5Hz,Ar-H),7.88(1H,dd,J＝8.4,1.5Hz, Ar-H),8.54(1H,t,J＝1.5Hz,Ar-H),9.44(1H,dd,J＝8.7,1.5Hz,Ar-H).13C NMR (75MHz,CDCl3):δ(ppm)24.89,50.52,121.90,124.97,125.17,126.92,127.33, 128.42,128.84,130.09,131.77,131.92,133.10,133.32,144.73,154.62,159.91, 181.07(CO).HRMS(ESI)calcd for C20H15N2OSCl[M]+366.0594；found[M+H]+ 367.0659.
实施例20
10-氯-6-(2-氧代哌啶-1-基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(21)
10-Chloro-6-(2-oxopiperidin-1-yl)-12H-thiochromeno[2,3-c]quinolin-12-one (21)
取化合物3(0.33g,1.0mmol)与piperidin-2-one(5.55mmol)与碳酸钠(5mmol) 溶于DMF(15mL)，回流10小时(TLC监控)。静置10分钟冷却后，反应物加入 100mL冰水中。过滤出沉淀物后，以水及甲醇清洗收集得到黄色固体。分离出黄色固体(产率89％)。Mp:258-261℃.1H NMR(400MHz,CDCl3):δppm.1.25 (1H,d,J＝4.8Hz,piperidone-H),2.44(2H,quin,-CH2-),2.61(1H,s,piperidone-H), 2.75(2H,t,J＝8.4Hz,-CH2-),4.11-4.14(2H,m,-CH2-),7.60-7.67(2H,m,Ar-H), 7.78-7.81(2H,m,Ar-H),8.09-8.12(1H,m,Ar-H),8.60(1H,d,J＝2.0Hz,Ar-H), 9.72-9.75(1H,m,Ar-H).13C NMR(100MHz,CDCl3):δppm.19.37,31.47,41.05, 49.14,125.25,126.08,127.65,129.29,129.51,129.80,129.88,130.74,131.96, 132.26,132.74,133.47,133.91,145.05,148.08,176.14,181.01.
实施例21
10-氯-6-甲基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N1)
10-Chloro-6-methylamino-12H-thiochromeno[2,3-c]quinolin-12-one(N1)
分离出黄色固体(产率92％)。(Rf＝0.65at CH2Cl2).Mp 237-238℃(MeOH). 1HNMR(400MHz,CDCl3):δ(ppm)3.26(3H,d,J＝4.8Hz,-CH3),4.92(1H,d,J＝ 4.8Hz,-NH-),7.45(1H,td,J＝11.2,1.6Hz,Ar-H),7.58(1H,d,J＝8.4Hz,Ar-H), 7.69-7.65(2H,m,Ar-H),7.86(1H,dd,J＝8.4,0.8Hz,Ar-H),8.56(1H,d,J＝1.6Hz, Ar-H),9.45(1H,dd,J＝8.4,1.2Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm) 29.38,120.73,123.68,124.65,125.87,127.18,127.49,129.38,129.51,129.62, 131.04,132.50,132.53,134.14,145.64,151.21,180.96(CO).HRMS(ESI)m/z calcd for C17H11N2OSCl[M]+:326.0281,found[M+H]+:327.0356.
实施例22
10-氯-6-乙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N2)
10-Chloro-6-ethylamino-12H-thiochromeno[2,3-c]quinolin-12-one(N2)
分离出黄色固体(产率91％)。(Rf＝0.75at CH2Cl2).Mp 204-205℃(MeOH). 1HNMR(400MHz,CDCl3):δ(ppm)1.41(3H,t,J＝7.2Hz,-CH3),3.75(2H,q,J＝ 1.6Hz,-CH2 -),4.81(1H,br,-NH-),7.44(1H,td,J＝8.4,1.6Hz,Ar-H),7.58-7.64 (3H,m,Ar-H),7.83(1H,d,J＝8.4Hz,Ar-H),8.56(1H,d,J＝1.6Hz,Ar-H),9.44 (1H,d,J＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)14.79,37.28, 120.70,123.50,124.58,125.84,127.18,127.47,129.39,129.47,129.66,131.08, 132.50,132.53,134.12,145.67,150.55,181.00(CO).HRMS(ESI)m/z calcd for C18H13N2OSCl[M]+:340.0437,found[M+H]+:341.0493.
实施例23
10-氯-6-丙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N3)
10-Chloro-6-propylamino-12H-thiochromeno[2,3-c]quinolin-12-one(N3) 分离出黄色固体(产率85％)。(Rf＝0.82at CH2Cl2).Mp 178-179℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.09(3H,t,J＝7.2Hz,-CH3),1.81(2H,sext,J＝ 7.2Hz,-CH2-),3.69(2H,q,J＝7.2Hz,-NCH2-),4.87(1H,br,-NH-),7.44(1H,td,J ＝8.0,1.2Hz,Ar-H),7.58-7.64(3H,m,Ar-H),7.82(1H,d,J＝8.0Hz,Ar-H),8.56 (1H,d,J＝1.2Hz,Ar-H),9.44(1H,d,J＝8.8Hz,Ar-H).13C NMR(100MHz, CDCl3):δ(ppm)11.68,22.64,44.13,120.67,123.53,124.53,125.82,127.15,127.46, 129.38,129.46,129.65,131.05,132.49,134.10,145.66,150.62,181.02(CO).HRMS (ESI)m/z calcd for C19H15N2OSCl[M]+:354.0594,found[M+H]+:355.0651.
实施例24
6-(丁基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N4)
6-(Butylamino)-10-chloro-12H-thiochromeno[2,3-c]quinolin-12-one(N4)
分离出黄色固体(产率91％)。(Rf＝0.85at CH2Cl2).Mp 147-149℃(MeOH). 1HNMR(400MHz,CDCl3):δ(ppm)1.03(3H,t,J＝7.2Hz,-CH3),1.53(2H,sext,J ＝7.2Hz,-CH2-),1.76(2H,quin,J＝7.2Hz,-CH2-),3.71(2H,q,J＝6.8Hz, -NCH2-),4.83(1H,br,-NH-),7.43(1H,td,J＝7.6,1.2Hz,Ar-H),7.57-7.64(3H,m, Ar-H),7.82(1H,d,J＝8.4Hz,Ar-H),8.55(1H,d,J＝1.6Hz,Ar-H),9.43(1H,d,J ＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)13.97,20.36,31.54,42.12, 120.67,123.53,124.52,125.84,127.16,127.46,129.38,129.46,129.65,131.05, 132.48,132.52,134.11,145.68,150.62,181.00(CO).HRMS(ESI)m/z calcd for C20H17N2OSCl[M]+:368.0750,found[M+H]+:369.0846.
实施例25
10-氯-6-异丁基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N5)
10-Chloro-6-isobutylamino-12H-thiochromeno[2,3-c]quinolin-12-one(N5)
分离出黄色固体(产率61％)。(Rf＝0.85at CH2Cl2).Mp 159-160℃(MeOH). 1HNMR(400MHz,CDCl3):δ(ppm)1.08(6H,d,J＝6.8Hz,-CH3),2.10(1H,sep,J ＝6.8Hz,-CH-),3.56(2H,t,J＝6.4Hz,-CH2-),4.94(1H,br,-NH),7.44(1H,t,J＝7.2 Hz,Ar-H),7.59-7.64(3H,m,Ar-H),7.82(1H,d,J＝8.4Hz,Ar-H),8.57(1H,dd,J＝ 2.0,0.8Hz,Ar-H),9.43(1H,d,J＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ (ppm)20.50,28.16,49.72,120.67,123.54,124.51,125.82,127.13,127.47,129.39, 129.47,129.69,131.02,132.50,134.11,138.34,145.62,150.68,181.02(CO).HRMS (ESI)m/z calcd for C20H17N2OSCl[M]+:368.0750,found[M+H]+:369.0825.
实施例26
10-氯-6-(戊-3-基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N6)
10-Chloro-6-(pentan-3-ylamino)-12H-thiochromeno[2,3-c]quinolin-12-one(N6)
分离出黄色固体(产率65％)。(Rf＝0.87at CH2Cl2).Mp 160-161℃(MeOH). 1HNMR(400MHz,CDCl3):δ(ppm)0.92(6H,t,J＝7.6Hz,-CH3),1.69(4H,quin, J＝6.0Hz,-CH2-),4.34(1H,sext,J＝7.2Hz,-CH-),6.58(1H,d,J＝8.0Hz,Ar-H), 7.36(1H,t,J＝8.0Hz,Ar-H),7.58(1H,t,J＝8.0Hz,Ar-H),7.65(1H,d,J＝8.0Hz, Ar-H),7.90(1H,dd,J＝8.4,2.4Hz,Ar-H),8.01(1H,d,J＝8.4Hz,Ar-H),8.40(1H, d,J＝2.4Hz,Ar-H),9.34(1H,d,J＝8.8Hz,Ar-H).13C NMR(100MHz,CDCl3):δ (ppm)11.21,26.86,54.41,120.16,123.92,125.13,125.81,127.05,128.49,129.02, 129.37,129.73,132.17,132.55,133.22,133.29,145.69,151.64,180.85(CO).HRMS (ESI)m/z calcd for C21H19N2OSCl[M]+:382.0907,found[M+H]+:383.0994, [M-H]–:381.0851.
实施例27
10-氯-6-((2-(二甲基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N7)
10-Chloro-6-((2-(dimethylamino)ethyl)amino)-12H-thiochromeno[2,3-c]quinoli n-12-one(N7)
分离出黄色固体(产率76％)。(Rf＝0.82at EA:MeOH:ammonia water＝10:5:1).Mp 156-157℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)2.36(6H,s, -N(CH3)2),2.69(2H,t,J＝6.0Hz,-CH2N-),3.57(2H,q,J＝5.6Hz,-NCH2-),5.86 (1H,br,-NH),7.44(1H,td,J＝8.0,1.6Hz,Ar-H),7.62(2H,td,J＝7.6,1.6Hz, Ar-H),7.65(1H,dd,J＝8.0,0.8Hz,Ar-H),7.82(1H,dd,J＝8.4,1.2Hz,Ar-H),8.58 (1H,dd,J＝1.6,0.4Hz,Ar-H),9.46(1H,dd,J＝8.8,1.2Hz,Ar-H).13C NMR(100 MHz,CDCl3):δ(ppm)39.53,45.28,57.57,120.71,123.46,125.90,127.02,127.27, 127.57,129.35,129.43,129.56,131.46,132.43,132.56,134.02,145.72,150.90, 181.05.(CO).HRMS(ESI)m/z calcd for C20H18N3OSCl[M]+:383.0859,found [M+H]+:384.0925.
实施例28
10-氯-6-((2-(二乙基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N8)
10-Chloro-6-((2-(diethylamino)ethyl)amino)-12H-thiochromeno[2,3-c]quinolin- 12-one(N8)
分离出黄色固体(产率86％)。(Rf＝0.8at EA:MeOH:ammonia water＝10:5:1).Mp 152-153℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.13(6H,t,J＝7.2 Hz,-CH3),2.64(4H,q,J＝6.8Hz,-NCH2-),2.82(2H,t,J＝6.0Hz,-CH2N-),3.70 (2H,q,J＝5.2Hz,-NCH2-),6.08(1H,br,-NH-),7.43(1H,t,J＝7.2Hz,Ar-H), 7.59-7.64(3H,m,Ar-H),7.81(1H,d,J＝8.4Hz,Ar-H),8.57(1H,d,J＝1.2Hz, Ar-H),9.45(1H,d,J＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)12.34, 39.52,46.81,50.89,120.64,124.25,124.34,125.89,126.96,127.63,129.32,129.41, 129.53,131.49,132.37,132.55,133.98,145.79,150.96,181.06(CO).HRMS(ESI) m/z calcd for C22H22N3OSCl[M]+:411.1172,found[M+H]+:412.1262.
实施例29
10-氯-6-(2-乙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N9)
10-Chloro-6-(2-ethanolamino)-12H-thiochromeno[2,3-c]quinolin-12-one(N9)
分离出黄色固体(产率77％)。(Rf＝0.65at EA).Mp 190-192℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)3.93(2H,q,J＝4.4Hz,-NCH2-),4.00(2H,t,J＝ 4.4Hz,-CH2O-),4.23(1H,br,-OH),5.45(1H,br,-NH),7.48(1H,td,J＝8.0,1.6Hz, Ar-H),7.62-7.68(3H,m,Ar-H),7.81(1H,dd,J＝7.6,0.8Hz,Ar-H),8.58(1H,dd,J＝ 1.6,0.4Hz,Ar-H),9.45(1H,dd,J＝8.4,0.8Hz,Ar-H).13C NMR(100MHz,CDCl3): δ(ppm)45.88,63.59,120.97,123.67,125.12,125.92,126.60,127.50,129.48,129.83, 130.15,130.91,132.55,132.69,134.35,144.65,151.32,180.87(CO).HRMS(ESI) m/z calcd for C18H13N2O2SCl[M]+:356.8260,found[M+H]+:357.0476,[M+H+2]+: 359.0455.
实施例30
10-氯-6-(3-丙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N10)
10-Chloro-6-(3-propanolamino)-12H-thiochromeno[2,3-c]quinolin-12-one(N10)
分离出黄色固体(产率94％)。(Rf＝0.66at EA).Mp 201-202℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.94(2H,p,J＝6.0Hz,-CH2-),3.72(2H,t,J＝ 5.2Hz,-NCH2-),3.93(2H,q,J＝6.0Hz,-CH2O-),4.41(1H,br,-OH),5.38(1H,t,J ＝5.2Hz,-NH-),7.45(1H,td,J＝7.6,1.2Hz,Ar-H),7.58-7.65(3H,m,Ar-H),7.78 (1H,dd,J＝8.4,0.8Hz,Ar-H),8.56(1H,dd,J＝2.0,0.4Hz,Ar-H),9.42(1H,dd,J ＝8.4,1.2Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)33.23,38.94,59.25, 120.72,123.44,124.84,125.94,126.32,127.45,129.44,129.92,130.11,130.84, 132.49,132.64,134.31,144.83,151.33,180.88(CO).HRMS(ESI)m/z calcd for C19H15N2O2SCl[M]+:370.0543,found[M+H]+:371.0622.
实施例31
10-氯-6-(5-戊醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N11)
10-Chloro-6-(5-pentanolamino)-12H-thiochromeno[2,3-c]quinolin-12-one(N11)
分离出黄色固体(产率91％)。(Rf＝0.7at EA).Mp 158-160℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.40(1H,br,-OH),1.49-1.62(2H,m,-CH2-),1.71 (2H,quin,-CH2-),1.83(2H,quin,-CH2-),3.74(4H,quin,-CH2-),4.91(1H,br,-NH), 7.45(1H,td,J＝7.6,1.2Hz,Ar-H),7.59(3H,m,Ar-H),7.83(1H,d,J＝8.4Hz, Ar-H),8.57(1H,d,J＝1.2Hz,Ar-H),9.44(1H,d,J＝8.4Hz,Ar-H).13C NMR(100 MHz,CDCl3):δ(ppm)23.39,29.17,32.40,42.24,62.83,120.69,123.53,124.60, 125.84,127.11,127.48,129.40,129.51,129.71,131.02,131.79,132.53,134.14, 145.60,150.58,181.02(CO).HRMS(ESI)m/z calcd forC21H19N2O2SCl[M]+: 398.0856,found[M+H]+:399.0914.
实施例32
10-氯-6-((1-羟基丁烷-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N12)
10-Chloro-6-((1-hydroxybutan-2-yl)amino)-12H-thiochromeno[2,3-c]quinolin-1 2-one(N12)
分离出黄色固体(产率94％)。(Rf＝0.8at EA).Mp 203-204℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.21(3H,t,J＝7.6Hz,-CH3),1.71-1.88(2H,m, -CH2-),3.79(1H,dd,J＝11.2,1.6Hz,-CH2-),3.99(1H,dd,J＝11.2,2.8Hz,-CH2-), 4.34(1H,quin,J＝11.2Hz,-NCH-),4.59(1H,br,-OH),5.02(1H,d,J＝6.0Hz, -NH-),7.44(1H,td,J＝8.0,1.2Hz,Ar-H),7.56(1H,d,J＝8.4Hz,Ar-H),7.59(1H, td,J＝7.6,1.2Hz,Ar-H),7.61(1H,d,J＝8.4Hz,Ar-H),7.74(1H,d,J＝8.4Hz, Ar-H),8.52(1H,d,J＝2.0Hz,Ar-H),9.40(1H,dd,J＝7.6,1.2Hz,Ar-H).13C NMR (100MHz,CDCl3):δ(ppm)10.95,24.95,56.89,67.08,120.83,123.68,124.98, 125.88,126.51,127.40,129.39,129.75,130.02,130.81,132.38,132.62,134.28, 144.53,151.09,180.75(CO).HRMS(ESI)m/z calcd forC20H17N2O2SCl[M]+: 384.0699,found[M+H]+:385.0790.
实施例33
10-氯-6-((4-甲基戊-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N13)
10-Chloro-6-((4-methylpentan-2-yl)amino)-12H-thiochromeno[2,3-c]quinolin-1 2-one(N13)
分离出黄色固体(产率94％)。(Rf＝0.9at CH2Cl2).Mp 176-177℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)0.98(3H,d,J＝6.8Hz,-CH3),1.03(3H,d,J＝ 6.8Hz,-CH3),1.35(3H,d,J＝6.4Hz,-CH3),1.45(1H,quin,J＝6.4Hz,-CH2-), 1.66(1H,quin,J＝6.8Hz,-CH2-),1.80(1H,sep,J＝6.8Hz,-CH-),4.63(1H,br, -NH),4.63-4.66(1H,m,-CH-),7.43(1H,td,J＝7.6,1.2Hz,Ar-H),7.58-7.63(3H, m,Ar-H),7.81(1H,d,J＝8.4Hz,Ar-H),8.56(1H,d,J＝1.2Hz,Ar-H),9.43(1H,d, J＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)21.38,22.87,22.92,25.40, 45.73,46.80,120.55,123.42,124.36,125.80,127.21,127.44,129.38,129.71,131.08, 132.47,132.52,134.07,145.76,150.01,181.05(CO).HRMS(ESI)m/z calcd for C22H19N2OSCl[M]+:396.1063,found[M+H]+:397.1142.
实施例34
6-((2-氨基乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N14)
6-((2-Aminoethyl)amino)-10-chloro-12H-thiochromeno[2,3-c]quinolin-12-one (N14)
分离出黄色固体(产率90％)。(Rf＝0.6at EA:MeOH:ammonia water＝10:5: 1).Mp 193-194℃(MeOH).1H NMR(400MHz,DMSO-d6):δ(ppm)2.90(2H,t,J ＝6.0Hz,-CH2-),3.59(2H,t,J＝6.0Hz,-CH2-),7.36(1H,t,J＝8.0Hz,Ar-H), 7.59(1H,t,J＝8.0Hz,Ar-H),7.66(1H,d,J＝8.0Hz,Ar-H),7.85(1H,d,J＝7.2Hz, Ar-H),7.96(1H,d,J＝8.8Hz,Ar-H),8.35(1H,br,Ar-H),9.32(1H,d,J＝8.4Hz, Ar-H).13C NMR(100MHz,DMSO-d6):δ(ppm)40.79,45.06,120.24,124.08, 125.31,125.84,127.00,128.39,128.83,129.32,129.69,132.06,132.33,133.12, 133.26,145.58,151.52,180.65(CO).HRMS(ESI)m/z calcd forC18H14N3OSCl [M]+:355.0546,found[M+H]+:356.0641.
实施例35
10-氯-6-((2-((2-羟乙基)氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮 (N15)
10-Chloro-6-((2-((2-hydroxyethyl)amino)ethyl)amino)-12H-thiochromeno[2,3-c ]quinolin-12-one(N15)
分离出黄色固体(产率58％)。(Rf＝0.63at EA:MeOH:ammonia water＝10:5: 1).Mp 141-143℃(MeOH).1H NMR(400MHz,DMSO-d6):δ(ppm)2.69(2H,t,J ＝5.6Hz,-CH2-),2.90(2H,t,J＝6.0Hz,-CH2-),3.51(2H,t,J＝5.6Hz,-CH2-),3.65 (2H,t,J＝6.0Hz,-CH2-),7.10(1H,br,-NH-),7.32(1H,t,J＝7.2Hz,Ar-H),7.55 (1H,t,J＝7.2Hz,Ar-H),7.62(1H,d,J＝8.4Hz,Ar-H),7.76(1H,t,J＝7.2Hz, Ar-H),7.86(1H,d,J＝8.4Hz,Ar-H),8.25(1H,d,J＝2.0Hz,Ar-H),9.26(1H,d,J ＝8.4Hz,Ar-H).13C NMR(100MHz,DMSO-d6):δ(ppm)41.90,48.16,51.80,60.72, 120.13,123.96,125.14,125.81,126.94,128.26,128.65,129.16,129.60,131.82, 132.11,132.96,133.19,145.50,151.35,180.45(CO).HRMS(ESI)m/z calcd for C20H18N3O2SCl[M]+:399.8938,found[M+H]+:400.0880.
实施例36
10-氯-6-((2-吗啉代乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N16)
10-Chloro-6-((2-morpholinoethyl)amino)-12H-thiochromeno[2,3-c]quinolin-12- one(N16)
分离出黄色固体(产率87％)。(Rf＝0.48at EA).Mp 189-190℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)2.63(4H,br,-CH2-),2.81(2H,br,-CH2-),3.81 (6H,br,-CH2-),5.92(1H,br,-NH-),6.70(2H,d,J＝8.4Hz,Ar’-H),7.45(1H,td,J ＝7.8,1.6Hz,Ar-H),7.60-7.64(3H,m,Ar-H),7.81(1H,d,J＝8.4Hz,Ar-H),8.57 (1H,s,Ar-H),9.46(1H,dd,J＝8.8,1.2Hz,Ar-H).13C NMR(100MHz,CDCl3):δ (ppm)38.28,53.31,56.52,67.13,120.73,123.94,124.58,125.91,127.01,127.56, 129.37,129.49,129.64,131.27,132.47,132.54,134.10,145.66,150.76,180.99(CO). HRMS(ESI)m/z calcd for C22H20N3O2SCl[M]+:425.0965,found[M+H]+:426.1058, [M-H]-:424.0885.
实施例37
10-氯-6-((3-(二甲基氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N17)
10-Chloro-6-((3-(dimethylamino)propyl)amino)-12H-thiochromeno[2,3-c]quino lin-12-one(N17)
分离出黄色固体(产率43％)。(Rf＝0.71at EA:MeOH:ammonia water＝10:5: 1).Mp 194-195℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.92(2H,quin,J ＝6.0Hz,-CH2-),2.41(6H,s,-N(CH3)2),2.60(2H,t,J＝5.6Hz,-CH2N-),3.81(2H, q,J＝5.6Hz,-NCH2-),7.95(1H,br,-NH),7.40(1H,td,J＝7.6,1.6Hz,Ar-H), 7.56-7.63(4H,m,Ar-H),7.80(1H,d,J＝8.4Hz,Ar-H),8.57(1H,d,J＝2.4Hz, Ar-H),9.44(1H,dd,J＝7.6,0.8Hz,Ar-H).13CNMR(100MHz,CDCl3):δ(ppm) 24.83,43.64,45.68,59.72,120.46,123.97,124.56,125.84,126.83,127.54,129.32, 129.48,131.84,132.29,132.56,133.86,146.01,151.27,181.14(CO).HRMS(ESI) m/z calcd for C21H20N3OSCl[M]+:397.1016,found[M+H]+:398.1072.
实施例38
10-氯-6-((3-(二乙氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N18)
10-Chloro-6-((3-(diethylamino)propyl)amino)-12H-thiochromeno[2,3-c]quinoli n-12-one(N18)
分离出黄色固体(产率70％)。(Rf＝0.68at EA:MeOH:ammonia water＝10:5: 1).Mp 142-143℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.15(6H,t,J＝ 6.8Hz,-CH3),1.91(2H,quin,J＝6.0Hz,-CH2-),2.66-2.72(6H,m,-NCH2-),3.81 (2H,q,J＝4.8Hz,-NCH2-),7.40(1H,td,J＝7.2,1.2Hz,Ar-H),7.55-7.58(1H,dd,J ＝8.4,3.6Hz,Ar-H),7.60-7.64(2H,m,Ar-H),7.81(1H,d,J＝8.0Hz,Ar-H),7.93 (1H,br,Ar-H),8.58(1H,t,J＝2.0Hz,Ar-H),9.45(1H,dd,J＝8.4,0.8Hz,Ar-H). 13C NMR(100MHz,CDCl3):δ(ppm)11.44,24.71,44.25,47.09,53.57,120.45, 123.99,124.50,125.86,126.87,127.46,129.34,129.43,131.85,132.32,132.57, 133.88,146.04,151.30,181.15(CO).HRMS(ESI)m/z calcd forC23H24N3SOCl [M]+:425.1329,found[M+H]+:426.1396,[M-H]–:424.1284.
实施例39
10-氯-6-((3-((2-羟乙基)氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮 (N19)
10-Chloro-6-((3-((2-hydroxyethyl)amino)propyl)amino)-12H-thiochromeno[2,3- c]quinolin-12-one(N19)
分离出黄褐色固体(产率75％)。(Rf＝0.65at EA:MeOH:ammonia water＝10: 5:1).Mp 65-67℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.89(2H,quin,J ＝6.0Hz,-CH2-),2.15(2H,br,-OH&-NH-),2.85(4H,quin,-CH2-),3.74(2H,t,J＝ 6.0Hz,-CH2-),3.80(2H,t,J＝5.2Hz,-CH2-),6.53(1H,br,-NH-),7.39(1H,td,J＝ 7.6,0.8Hz,Ar-H),7.44(1H,d,J＝8.8Hz,Ar-H),7.50(1H,dd,J＝8.4,2.4Hz, Ar-H),7.58(1H,td,J＝7.2,1.2Hz,Ar-H),7.76(1H,d,J＝8.0Hz,Ar-H),8.46(1H, d,J＝2.0Hz,Ar-H),9.39(1H,d,J＝8.4Hz,Ar-H).13CNMR(100MHz,CDCl3):δ (ppm)28.37,42.23,48.74,51.65,61.42,120.48,123.99,124.22,125.85,126.88, 127.42,129.13,129.33,129.38,131.23,132.21,132.33,133.95,145.69,150.82, 180.92(CO).HRMS(ESI)m/z calcd for C21H20N3O2SCl[M]+:413.0965,found [M+H]+:414.1053,[M+H+2]+:416.1037.
实施例40
10-氯-6-((2,3-二氢-1H-茚-2-基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N20)
10-Chloro-6-((2,3-dihydro-1H-inden-2-yl)amino)-12H-thiochromeno[2,3-c]quin olin-12-one(N20)
分离出黄褐色固体(产率65％)。(Rf＝0.7at CH2Cl2:n-hexane＝2:1).Mp 251-252℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)3.02(1H,d,J＝5.2Hz, indane-H),3.06(1H,d,J＝5.2Hz,indane-H),3.59(1H,d,J＝7.2Hz,indane-H), 3.63(1H,d,J＝7.2Hz,indane-H),5.10(1H,d,J＝6.8Hz,-NH),5.23(1H,q,J＝ 5.2Hz,indane-H),7.21-7.25(2H,m,Ar’-H),7.28-7.31(2H,m,Ar’-H),7.47(1H,td, J＝6.8,1.2Hz,Ar-H),7.58(1H,d,J＝8.4Hz,Ar-H),7.61-7.67(1H,td,J＝6.8,1.2 Hz,Ar-H),7.87(1H,d,J＝7.6Hz,Ar-H),8.57(1H,d,J＝2.0Hz,Ar-H),9.46(1H, dd,J＝8.8,0.8Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)40.41,53.27, 120.79,123.60,124.81,124.93,125.84,126.76,127.37,127.46,129.38,129.51,129.71,131.02,132.50,132.54,134.12,141.29,145.56,150.20,181.00(CO).HRMS (ESI)m/z calcd for C25H17N2OSCl[M]+:428.0750；found[M+H]+:429.0822.
实施例41
10-氯-6-(环己基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N21)
10-Chloro-6-(cyclohexylamino)-12H-thiochromeno[2,3-c]quinolin-12-one(N21)
分离出黄褐色固体(产率91％)。(Rf＝0.7at CH2Cl2:n-hexane＝2:1).Mp 196-197℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.25-1.40(4H,m, cyclohexylamine-CH2),1.49-1.60(2H,m,cyclohexylamine-CH2),1.70-1.74(2H,m, cyclohexylamine-CH2),1.79-1.84(2H,m,cyclohexylamine-CH2),2.21(2H,dd,J＝ 8.8,3.2Hz,cyclohexylamine-CH2),4.30(1H,sep,J＝3.6Hz,cyclohexylamine-CH), 4.72(1H,d,J＝6.8Hz,-NH-),7.41(1H,t,J＝8.0Hz,Ar-H),7.51-62(3H,m,Ar-H), 7.79(1H,d,J＝8.0Hz,Ar-H),8.51(1H,d,J＝1.6Hz,Ar-H),9.41(1H,d,J＝8.4 Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)24.94,25.92,33.10,50.26,120.51, 123.50,124.34,125.77,127.11,127.37,129.27,129.35,129.60,131.01,132.37, 132.41,134.00,145.66,149.75,180.95(CO).HRMS(ESI)m/z calcd forC22H19N2OSCl[M]+:394.0907；found[M+H]+:395.0991.
实施例42
6-((1-芐基哌啶-4-基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N22)
6-((1-Benzylpiperidin-4-yl)amino)-10-chloro-12H-thiochromeno[2,3-c]quinolin- 12-one(N22)
分离出黄褐色固体(产率62％)。(Rf＝0.77at EA).Mp 194-196℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.62-1.72(2H,m,piperidine-H),2.24(2H,d,J＝ 13.2Hz,piperidine-H),2.32(2H,t,J＝11.2Hz,piperidine-H),2.92(2H,d,J＝11.6 Hz,piperidine-H),3.59(2H,s,-CH2-),4.35(1H,sext,J＝6.4Hz,piperidine-CH), 4.75(1H,d,J＝7.2Hz,-NH),7.26-7.30(1H,m,Ar’-H),7.36-7.38(4H,m,Ar’-H), 7.44(1H,td,J＝7.6,0.8Hz,Ar-H),7.59-7.64(3H,m,Ar-H),7.80(1H,d,J＝7.6Hz, Ar-H),8.56(1H,d,J＝1.6Hz,Ar-H),9.43(1H,d,J＝8.8Hz,Ar-H).13C NMR(100 MHz,CDCl3):δ(ppm)32.26,48.63,52.35,63.22,120.63,123.47,124.57,125.81, 127.07,127.12,127.47,128.25,129.21,129.35,129.44,129.74,130.99,132.46, 132.52,134.10,138.37,145.57,149.76,181.00(CO).HRMS(ESI)m/z calcd for C28H24N3OSCl[M]+:485.1329；found[M+H]+:486.1379.
实施例43
10-氯-6-((噻吩-2-基甲基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N23)
10-Chloro-6-((thiophen-2-ylmethyl)amino)-12H-thiochromeno[2,3-c]quinolin-1 2-one(N23)
分离出黄褐色固体(产率78％)。(Rf＝0.7at CH2Cl2:n-hexane＝2:1).Mp 178-180℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)5.07(1H,d,J＝5.2Hz, -NCH2-),5.17(1H,br,-NH-),7.00(1H,t,J＝4.4Hz,thiophene-H),7.16(1H,d,J＝ 3.2Hz,thiophene-H),7.25(1H,d,J＝0.8Hz,thiophene-H),7.47(1H,t,J＝8.0Hz, Ar-H),7.52(1H,d,J＝8.4Hz,Ar-H),7.58(1H,d,J＝8.4Hz,Ar-H),7.65(1H,t,J＝ 7.6Hz,Ar-H),7.89(1H,d,J＝8.0Hz,Ar-H),8.53(1H,s,Ar-H),9.46(1H,d,J＝8.4 Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)41.14,121.06,123.58,125.05, 125.47,125.89,126.47,126.73,127.29,127.45,129.33,129.57,129.71,130.94, 132.39,132.51,134.12,141.36,145.20,149.82,180.80(CO).HRMS(ESI)m/z calcd for C21H13N2OS2Cl[M]+:408.0158；found[M+H]+:409.0251,[M-H]–:407.0085.
实施例44
10-氯-6-((环己基甲基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N24)
10-Chloro-6-((cyclohexylmethyl)amino)-12H-thiochromeno[2,3-c]quinolin-12-o ne(N24)
分离出黄褐色固体(产率79％)。(Rf＝0.7at CH2Cl2:n-hexane＝2:1).Mp 165-166℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)1.07(1H,d,J＝11.2Hz, cyclohexyl-CH2),1.30(1H,d,J＝11.2Hz,cyclohexyl-CH2),1.23(2H,q,J＝11.6Hz, cyclohexyl-CH2),1.31(2H,q,J＝11.6Hz,cyclohexyl-CH2),1.78-1.81(4H,m, cyclohexyl-CH2),1.90(2H,d,J＝12.4Hz,cyclohexyl-CH2),3.53(2H,t,J＝6.0Hz, -NCH2-),4.85(1H,br,-NH-),7.40(1H,t,J＝7.2Hz,Ar-H),7.51(1H,d,J＝8.8Hz, Ar-H),7.55(1H,d,J＝1.6Hz,Ar-H),7.60(1H,t,J＝8.0Hz,Ar-H),7.79(1H,d,J＝ 8.0Hz,Ar-H),8.50(1H,d,J＝1.2Hz,Ar-H),9.41(1H,d,J＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)25.97,26.52,31.23,37.63,48.50,120.59,123.57, 124.41,125.80,127.10,127.38,129.26,129.38,129.45,130.95,132.33,132.41, 134.02,145.58,150.64,180.87(CO).HRMS(ESI)m/z calcd forC23H21N2OCl[M]+: 408.1063；found[M+H]+:409.1115.
实施例45
6-(芐基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N25)
6-(Benzylamino)-10-chloro-12H-thiochromeno[2,3-c]quinolin-12-one(N25)
分离出黄褐色固体(产率93％)。(Rf＝0.67at CH2Cl2:n-hexane＝2:1).Mp 194-195℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)4.94(2H,d,J＝5.2Hz, -CH2-),5.16(1H,br,-NH-),7.33-7.51(6H,m,Ar-H),7.58-7.67(3H,m,Ar-H),7.87 (1H,d,J＝8.0Hz,Ar-H),8.59(1H,d,J＝2.0Hz,Ar-H),9.47(1H,d,J＝8.0Hz, Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)37.63,120.98,123.54,124.89,125.87, 127.26,127.50,127.63,128.24,128.79,129.43,129.57,129.85,131.02,132.58, 134.18,138.82,145.48,150.33,181.00(CO).HRMS(ESI)m/z calcd for C23H15N2OSCl[M]+:402.0594；found[M+H]+:403.0692.
实施例46
10-氯-6-((吡啶-2-基甲基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮(N26)
10-Chloro-6-((pyridin-2-ylmethyl)amino)-12H-thiochromeno[2,3-c]quinolin-12- one(N26)
分离出黄褐色固体(产率93％)。(Rf＝0.25at EA).Mp 187-189℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)5.01(2H,d,J＝4.0Hz,-CH2-),6.79(1H,br, -NH-),7.24-7.28(1H,m,Ar’-H),7.45(2H,t,J＝7.2Hz,Ar’-H&Ar-H),7.61-7.67 (3H,m,Ar-H),7.73(1H,td,J＝7.6,1.6Hz,Ar-H),7.86(1H,d,J＝8.4Hz,Ar-H), 8.58(1H,d,J＝2.0Hz,Ar-H),8.67(1H,d,J＝4.8Hz,Ar’-H),9.47(1H,d,J＝8.4 Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)46.74,120.81,122.37,124.19, 124.61,125.93,127.04,127.60,129.33,129.44,129.60,131.40,132.46,132.52, 134.03,136.94,145.62,148.94,150.43,156.58,181.00(CO).HRMS(ESI)m/z calcd for C22H14N3OSCl[M]+:403.0546；found[M+H]+:404.0615.
实施例47
6-((苯并[d][1,3]二氧杂环戊烯-5-基甲基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c] 喹啉-12-酮(N27)
6-((Benzo[d][1,3]dioxol-5-ylmethyl)amino)-10-chloro-12H-thiochromeno[2,3-c ]quinolin-12-one(N27)
分离出黄褐色固体(产率90％)。(Rf＝0.88at EA).Mp 205-206℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)4.82(2H,t,J＝5.2Hz,-NCH2-),5.08(1H,br, -NH-),5.97(2H,s,-OCH2O-),6.82(1H,d,J＝8.0Hz,Ar’-H),6.96(1H,d,J＝8.0 Hz,Ar’-H),7.00(1H,d,J＝1.2Hz,Ar’-H),7.47(1H,td,J＝8.0,1.2Hz,Ar-H),7.57 (1H,d,J＝8.8Hz,Ar-H),7.60-7.66(2H,m,Ar-H),7.86(1H,d,J＝8.0Hz,Ar-H), 8.62(1H,d,J＝2.0Hz,Ar-H),9.46(1H,d,J＝8.8Hz,Ar-H).13C NMR(100MHz, CDCl3):δ(ppm)46.30,101.10,108.40,108.85,120.95,121.58,123.52,124.88, 125.86,127.23,127.46,129.39,129.56,129.76,130.98,132.48,132.55,132.61, 134.15,145.42,147.07,147.92,150.21,180.93(CO).HRMS(ESI)m/z calcd for C24H15N2O3SCl[M]+:446.0492；found[M+H]+:447.0586,[M-H]–:445.0440.
实施例48
10-氯-6-((2-甲氧芐基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮(N28)
10-Chloro-6-((2-methoxybenzyl)amino)-12H-thiochromeno[2,3-c]quinolin-12-o ne(N28)
分离出黄褐色固体(产率82％)。(Rf＝0.65at CH2Cl2:n-hexane＝2:1).Mp 223-224℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)3.95(3H,s,-OCH3), 4.93(2H,d,J＝5.6Hz,-NCH2-),5.57(1H,t,J＝5.6Hz,-NH-),5.97(2H,s, -OCH2O-),6.94-7.00(2H,m,Ar’-H),7.30(1H,td,J＝8.0,2.0Hz,Ar’-H),7.45(1H, td,J＝8.0,1.6Hz,Ar’-H),7.51(1H,d,J＝7.2Hz,Ar’-H),7.59-7.66(3H,m,Ar-H), 7.89(1H,dd,J＝8.4,1.2Hz,Ar-H),8.57(1H,dd,J＝2.0,0.8Hz,Ar-H),9.45(1H, dd,J＝8.4,0.8Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)42.33,55.49, 110.47,120.68,120.81,123.90,124.59,125.82,126.68,127.20,127.52,128.88, 129.38,129.44,129.71,130.49,131.23,132.46,132.54,134.04,145.59,150.62, 157.89,181.04(CO).HRMS(ESI)m/z calcd for C24H17N2O2SCl[M]+:432.0699；found[M+H]+:433.0783.
实施例49
10-氯-6-((3,4-二甲氧基芐基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮(N29)
10-Chloro-6-((3,4-dimethoxybenzyl)amino)-12H-thiochromeno[2,3-c]quinolin- 12-one(N29)
分离出黄褐色固体(产率84％)。(Rf＝0.66at CH2Cl2:n-hexane＝2:1).Mp 251-252℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)3.89(3H,s,-OCH3), 3.90(3H,s,-OCH3),4.86(2H,d,J＝4.8Hz,-NCH2-),5.11(1H,t,J＝5.2Hz,-NH-), 6.89(1H,d,J＝8.0Hz,Ar’-H),7.05(1H,dd,J＝8.0,2.0Hz,Ar’-H),7.08(1H,d,J ＝2.0Hz,Ar’-H),7.48(1H,td,J＝7.6,1.2Hz,Ar-H),7.60(1H,dd,J＝8.4,0.4Hz, Ar-H),7.65(1H,dd,J＝8.4,1.5Hz,Ar-H),7.66(1H,td,J＝8.0,1.2Hz,Ar-H),7.88 (1H,dd,J＝8.4,0.8Hz,Ar-H),8.59(1H,dd,J＝1.5,0.4Hz,Ar-H),9.48(1H,dd,J ＝8.4,1.2Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)46.45,55.96,55.99, 111.31,111.82,120.59,120.99,123.56,124.88,125.91,127.20,127.50,129.45, 129.60,129.88,131.04,131.34,132.59,134.21,145.52,148.63,149.20,150.34, 181.01(CO).HRMS(ESI)m/z calcd for C25H19N2O3SCl[M]+:462.0805；found [M+H]+:463.0900,[M-H]–:461.0754.
实施例50
10-氯-6-(苯乙基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N30)
10-Chloro-6-(phenethylamino)-12H-thiochromeno[2,3-c]quinolin-12-one(N30)
分离出黄褐色固体(产率94％)。(Rf＝0.52at CH2Cl2:n-hexane＝2:1).Mp 151-152℃(MeOH).1H NMR(400MHz,CDCl3):δ(ppm)3.10(2H,t,J＝6.8Hz, -CH2-),3.98(2H,q,J＝6.4Hz,-NCH2-),4.91(1H,t,J＝4.8Hz,-NH-),7.27-7.39 (5H,m,Ar’-H),7.45(1H,t,J＝8.0Hz,Ar-H),7.54(1H,d,J＝8.4Hz,Ar-H),7.59 (1H,d,J＝1.2Hz,Ar-H),7.63(1H,t,J＝7.6Hz,Ar-H),7.85(1H,d,J＝8.4Hz, Ar-H),8.54(1H,d,J＝1.6Hz,Ar-H),9.44(1H,d,J＝8.4Hz,Ar-H).13C NMR(100 MHz,CDCl3):δ(ppm)35.33,43.52,120.77,123.66,124.69,125.85,126.56,127.23, 127.50,128.73,128.94,129.33,129.48,129.50,131.03,132.54,134.08,139.30, 145.57,150.36,180.94(CO).HRMS(ESI)m/z calcd forC24H17N2OSCl[M]+: 416.9226；found[M+H]+:417.0857,[M+H+2]+:419.0834.
实施例51
10-氯-6-((4-甲氧基苯乙基)氨基)-12H–脱氢硫胺并[2,3-c]喹啉-12-酮(N31)
10-Chloro-6-((4-methoxyphenethyl)amino)-12H-thiochromeno[2,3-c]quinolin-1 2-one(N31)
分离出黄色固体(产率95％)。(Rf＝0.89at CH2Cl2).Mp 214-215℃(MeOH). 1HNMR(400MHz,CDCl3):δ(ppm)3.03(2H,t,J＝6.8Hz,-CH2-),3.81(3H,s, -OCH3),3.94(2H,q,J＝6.4Hz,-NCH2-),4.90(1H,t,J＝4.8Hz,-NH-),6.90(2H,d, J＝8.4Hz,Ar’-H),7.23(2H,d,J＝8.4Hz,Ar’-H),7.45(1H,t,J＝7.6Hz,Ar-H), 7.55(1H,d,J＝8.8Hz,Ar-H),7.59(1H,d,J＝2.0Hz,Ar-H),7.63(1H,t,J＝7.6Hz, Ar-H),7.85(1H,d,J＝8.0Hz,Ar-H),8.54(1H,d,J＝2.0Hz,Ar-H),9.44(1H,d,J ＝8.8Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)34.39,43.68,55.31,114.13, 120.76,123.67,124.67,125.85,127.22,127.52,129.36,129.49,129.68,129.87, 131.05,131.24,132.48,134.09,145.59,150.41,158.31,180.99(CO).HRMS(ESI) m/z calcd for C25H19N2O2SCl[M]+:446.0856；found[M+H]+:447.0938.
实施例52
6-((4-氨基苯乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N32)
6-((4-Aminophenethyl)amino)-10-chloro-12H-thiochromeno[2,3-c]quinolin-12- one(N32)
分离出黄色固体(产率82％)。(Rf＝0.52at CH2Cl2).Mp 208-210℃(MeOH). 1HNMR(400MHz,CDCl3):δ(ppm)2.97(2H,t,J＝6.8Hz,-CH2-),3.63(2H,br, -NH2),3.91(2H,q,J＝6.4Hz,-NCH2-),4.91(1H,t,J＝4.8Hz,-NH-),6.70(2H,d,J ＝8.4Hz,Ar’-H),7.09(2H,d,J＝8.0Hz,Ar’-H),7.44(1H,t,J＝7.6Hz,Ar-H), 7.55(1H,d,J＝8.0Hz,Ar-H),7.60(1H,d,J＝8.4Hz,Ar-H),7.63(1H,t,J＝7.6Hz, Ar-H),7.84(1H,d,J＝8.0Hz,Ar-H),8.54(1H,d,J＝2.0Hz,Ar-H),9.44(1H,d,J ＝8.4Hz,Ar-H).13C NMR(100MHz,CDCl3):δ(ppm)34.37,43.70,115.52,120.72, 123.73,124.59,125.83,127.19,127.51,129.06,129.31,129.45,129.59,129.75, 131.09,132.42,134.04,144.89,145.60,150.45,180.96(CO).HRMS(ESI)m/z calcd for C24H16N3OSCl[M]+:431.0859；found[M+H]+:432.0950.
实施例53
2-(10-氯-12-氧代-12H-脱氢硫胺并[2,3-c]喹啉-6-基)胍
2-(10-Chloro-12-oxo-12H-thiochromeno[2,3-c]quinolin-6-yl)guanidine(N33)
分离出黄色固体(产率85％)。Mp:370℃.1H NMR(400MHz,DMSO-d6):δ ppm.7.40(3H,td,J＝8.4,1.2Hz,Ar-H&-NH2),7.59(1H,td,J＝8.7,1.2Hz,Ar-H), 7.59(1H,dd,J＝8.4,0.8Hz,Ar-H),7.83(1H,dd,J＝8.4,2.0Hz,Ar-H),7.95(1H,d, J＝8.8Hz,Ar-H),8.40(1H,d,J＝2.4Hz,Ar-H),9.49(1H,dd,J＝8.4,0.8Hz, Ar-H).13C NMR(100MHz,DMSO-d6):δppm.120.77,124.49,125.86,126.82, 128.11,128.60,129.21,129.85,132.13,132.52,132.68,136.17,136.80,144.49, 159.19,181.16.HRMS(ESI)calcd for C17H11N4OSCl[M]+354.0342；found[M+H]+ 355.0438.
实施例54
10-氯-6-(哌啶-1-基氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮(N34)
10-Chloro-6-(piperidin-1-ylamino)-12H-thiochromeno[2,3-c]quinolin-12-one (N34)
分离出黄色固体(产率60％)。Mp:180-181℃.1H NMR(400MHz,CDCl3):δ ppm 1.72-1.74(2H,m,-CH2-),1.89(4H,quin,J＝5.2Hz,-CH2-),3.32(4H,J＝4.8 Hz,-CH2-),7.36(1H,tt,J＝8.7,2.1Hz,Ar-H10),7.47(1H,dd,J＝8.4,2.7Hz,Ar-H8), 7.61-7.73(3H,m,Ar-H),8.00(1H,d,J＝8.0Hz,Ar-H),8.59(1H,d,J＝2.0Hz, Ar-H),9.63(1H,d,J＝8.8Hz,Ar-H).13C NMR(100MHz,CDCl3):δppm,24.28, 25.91,52.36,123.49,125.77,127.32,127.90,128.59,129.06,129.27,130.51,131.66, 132.18,132.39,133.49,134.70,144.98,158.53,181.58.
药理活性实验
在药理试验方面，将化学合成出的化合物结构2-21与N-1至N-34(共54 种药物)，进行下列五个部份的药理活性试验：一、细胞存活分析(MTT assay)试验；二、第一型、第二型拓朴异构酶活性试验；三、细胞周期阻滞；四、细胞凋亡相关蛋白表现量；五、美国癌症研究中心(NCI)筛选出26个化合物结构，针对这26个化合物进行60种癌细胞株的毒杀试验。
实施例55细胞存活分析(MTT assay)试验
所有的合成化合物利用MTT比色法，分析化合物于PC-3(BCRC 60122, Taiwan)与DU-145(HTB-81TM,ATCC,Rockville,MD)细胞株细胞毒性。上述细胞培养于RPMI-1640、5％FBS(v/v)、100U/mL青霉素与50mg/mL链霉素。于 96孔盘培养约2x103个细胞，5％CO2于37℃24小时。为了测量体外细胞毒性，所有的化合物皆于实验前溶于DMSO，并预先混和在相同的细胞培养液中以利给药，并调整好不同的给药浓度(0.15、0.5、1.5、5、15μM)进行三重复实验。给药后72小时，100μL的MTT(1mg/mL)加入每个孔中，并在培养于37℃ 4小时。移除MTT溶液后，加入100μL的DMSO至每一孔中，再培养于37℃ 20分钟。以ELISA读取机侦测吸收光谱为560nm的数值。结果以至少三重复的平均值呈现，表1呈现IC50数值。
表1、利用MTT分析出脱氢硫胺[2,3-c]喹啉-12-酮衍生物的细胞毒性
a SD:标准差，所有实验皆至少三重复。
此外，相较于只有单一羟基、烷基或芳香环，化合物N7、N8、N14、N15、N17及N18含有至少一个氮原子在侧支链，显示具有较优异的细胞毒杀活性。化合物5、7、8、16、19、N2、N7、N8、N9、N14、N15、N16、N17、N18、 N19及N25被筛选进行拓朴异构酶活性试验。
实施例56第一、二型拓朴异构酶活性试验
化合物5、7、8、16、19、N2、N7、N8、N9、N14、N15、N16、N17、N18、 N19及N25以25μM或50μM以进行拓朴异构酶活性试验(图2-4)。
于第一型拓朴异构酶活性试验中，化合物7、N7、N14、N15、N17、N18 与N25相较于喜树碱为更具有抑制效果，并进一步以五种不同浓度进行实验(图 4a-d)。化合物7、N7、N14、N15、N17、N18与N25的IC50值分别为10、10、 1、5、25、5与25μM(使用TopoGEN TG2005H、TG-2000H-1所测得)。
于第二型拓朴异构酶活性试验中(图5-7)，化合物7、N7、N8、N14、N15、 N18与N19相较于喜树碱为更具有抑制效果，并进一步以五种不同浓度进行实验(图7a-d)。化合物7、N7、N8、N14、N15、N18与N19的IC50值分别为10、 10、1、10、5、1与1μM(使用TopoGEN TG2005H、TG-2000H-1所测得)。
实施例57美国癌症研究中心(NCI)筛选
美国癌症研究中心(NCI)筛选出26个化合物结构(2、3、4、5、6、8、10、 11、12、13、N1、N2、N6、N7、N9、N12、N13、N14、N16、N17、N19、N21、 N25、N27、N30、N31)，针对这26个化合物进行60种癌细胞株的毒杀试验。第一阶段先进行26个化合物于10μM的毒杀试验，进行六十种癌细胞株的毒杀试验，作用48小时后进行细胞存活试验(Sulforhodamine B，SRB)。结果如表2- 表4，以生长百分比(growth percent)作为表示。
之后从中找出较具有毒杀潜力的化合物结构共5个：N2、N7、N14、N19 与N25进行第二阶段五种浓度(0.01、0.1、1、10、100μM)的毒杀试验(表5)。
表2、化合物2、3、4、5、6、8、10、11、12、13的NCI数据
a NCI 60种细胞体外药物筛选程序，各化合物的浓度为10-5M。
b N.T.＝No test。
表3、化合物N1、N2、N6、N7、N9、N12、N13、N14的NCI数据
a NCI 60种细胞体外药物筛选程序，各化合物的浓度为10-5M。
b N.T.＝No test。
表4、化合物N16、N17、N19、N21、N25、N27、N30、N31的NCI数据
a NCI 60种细胞体外药物筛选程序，各化合物的浓度为10-5M。
b N.T.＝No test。
表5、N2、N7、N14、N19、N25NCI的GI50、TGI、LC50数据
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对本发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。
Claims (8)
1.一种式(I)化合物，
其中R是选自下列取代基所组成的群组：
2.根据权利要求1的化合物，其特征在于，其中该化合物是选自由下列所组成的群组：
10-氯-6-乙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二甲基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二乙基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(2-乙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(3-丙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(5-戊醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((2-氨基乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-((2-羟乙基)氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-吗啉代乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二甲基氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二乙氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-((2-羟乙基)氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(芐基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮。
3.一种医药组合物，其特征在于，包含治疗有效量的如权利要求1所述的化合物，和至少一种医药上可接受载剂、稀释剂或赋形剂。
4.一种如权利要求1或2所述的化合物的用途，其特征在于，其是用于制造可用于抑制第一型拓朴异构酶活性的医药品。
5.一种如权利要求1或2所述的化合物的用途，其特征在于，其是用于制造可用于抑制第二型拓朴异构酶活性的医药品。
6.一种如权利要求1或2所述的化合物的用途，其特征在于，其是用于制造可用于治疗癌症的医药品。
7.根据权利要求6所述的用途，其特征在于，其中该癌症是选自白血病、非小细胞肺癌、大肠癌、中枢神经癌、黑色素瘤、卵巢癌、肾脏癌、前列腺癌及乳癌所组成的群组。
8.一种制造如权利要求1所述的化合物的方法，其特征在于，该方法包含：
(1)将靛红、2-((4-氯苯基)硫 代)醋酸及醋酸钠混合，于150℃反应1小时，将反应完的混合液冷却后加入醋酸得到沉淀物，再以醋酸、水、正己烷冲洗，得到化合物2，为3-((4-氯苯基)硫代)-2-羟基喹啉-4-羧酸；
(2)取化合物2即 3-((4-氯苯基)硫代)-2-羟基喹啉-4-羧酸溶于三氯氧磷，于150℃反应48小时，冷却后将反应物倒入水中，过滤收集沉淀物置入10％碳酸氢钠溶液搅拌1小时，收集沉淀物后再以水冲洗，粗产物以二氯甲烷再结晶，得到化合物3，为6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮；
(3)取化合物3即 6,10-二氯-12H-脱氢硫胺[2,3-c]喹啉-12-酮与一适当一级胺溶于DMSO，回流8小时，冷却后，反应物加入水中，过滤出沉淀物后，以水及甲醇清洗收集分别得到化合物N2，N7-N11，N14-N19，N25：
10-氯-6-乙基氨基-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二甲基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-(二乙基氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(2-乙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(3-丙醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-(5-戊醇氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-((2-氨基乙基)氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-((2-羟乙基)氨基)乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((2-吗啉代乙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二甲基氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-(二乙氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
10-氯-6-((3-((2-羟乙基)氨基)丙基)氨基)-12H-脱氢硫胺并[2,3-c]喹啉-12-酮、
6-(芐基氨基)-10-氯-12H-脱氢硫胺并[2,3-c]喹啉-12-酮。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410566281.7A CN104356142B (zh) | 2014-10-22 | 2014-10-22 | 脱氢硫胺[2,3‑c]喹啉‑12‑酮衍生物及其制备方法和应用 |
| HK15106836.8A HK1206334A1 (zh) | 2014-10-22 | 2015-07-17 | 脱氫硫胺 喹啉- -酮衍生物及其製備方法和應用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410566281.7A CN104356142B (zh) | 2014-10-22 | 2014-10-22 | 脱氢硫胺[2,3‑c]喹啉‑12‑酮衍生物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104356142A CN104356142A (zh) | 2015-02-18 |
| CN104356142B true CN104356142B (zh) | 2017-10-20 |
Family
ID=52523473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410566281.7A Active CN104356142B (zh) | 2014-10-22 | 2014-10-22 | 脱氢硫胺[2,3‑c]喹啉‑12‑酮衍生物及其制备方法和应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104356142B (zh) |
| HK (1) | HK1206334A1 (zh) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101326900B1 (ko) * | 2009-08-21 | 2013-11-11 | 이화여자대학교 산학협력단 | 신규한 항암제 보조용 화합물, 이의 제조방법 및 이를 포함하는 항암제 보조용 조성물 |
| CN103709122B (zh) * | 2013-11-29 | 2016-05-25 | 四川大学 | 用于治疗的抗肿瘤和抗真菌化合物 |
-
2014
- 2014-10-22 CN CN201410566281.7A patent/CN104356142B/zh active Active
-
2015
- 2015-07-17 HK HK15106836.8A patent/HK1206334A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1206334A1 (zh) | 2016-01-08 |
| CN104356142A (zh) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10968236B2 (en) | TYK2 inhibitors and uses thereof | |
| AU2019246753A1 (en) | Novel compounds and compositions for inhibition of FASN | |
| JP2017513954A (ja) | Ｉｒａｋ阻害剤およびその使用 | |
| WO2017004134A1 (en) | Irak inhibitors and uses thereof | |
| WO2017004133A1 (en) | Irak inhibitors and uses thereof | |
| CN106232122A (zh) | Irak抑制剂和其用途 | |
| JP2018511624A (ja) | Ｔａｍ ｒｔｋインヒビターとしてのキノリン誘導体 | |
| BRPI0913031A2 (pt) | derivados de quinolina e quinoxalinas como inibidores de proteína tirosina quinase, seus usos e processo de fabricação, bem como composições farmacêuticas e combinação que os compreende | |
| JP2008526804A (ja) | キナーゼ阻害剤としてのジ置換ウレア | |
| CA3115088A1 (en) | Tyk2 inhibitors and uses thereof | |
| JP6063909B2 (ja) | 新しいチオクロメノ［２，３−ｃ］キノリン−１２−オンの誘導体、調製方法及びその応用 | |
| AU2023282201A1 (en) | Chromene derivatives as inhibitors of TCR-Nck interaction | |
| CN104356142B (zh) | 脱氢硫胺[2,3‑c]喹啉‑12‑酮衍生物及其制备方法和应用 | |
| CA2982862A1 (en) | Preparation and use of kinase inhibitor | |
| TWI488843B (zh) | 新穎脱氫硫胺［２，３－ｃ］喹啉－１２－酮衍生物、其製備方法及其應用 | |
| EP3002287B1 (en) | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | |
| AU2015222590B2 (en) | Fused acridine derivative and pharmaceutical composition, preparation method and use thereof | |
| KR20160043348A (ko) | 신규한 티오크로메노[2,3-c]퀴놀린-12-온 유도체, 이의 제조 방법 및 응용 | |
| EA045073B1 (ru) | Производные хромена в качестве ингибиторов взаимодействия tcr-nck | |
| CA2866502A1 (en) | Thiochromeno(2,3-c)quinolin-12-one derivatives, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUANG XUSHAN Free format text: FORMER OWNER: AIYI BIOTECHNOLOGY CO., LTD. Effective date: 20150730 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150730 Address after: China Taiwan Taipei City Neihu district road six lane 135, 11 civil rights section No. 4 Lane Applicant after: Huang Xushan Address before: Chinese Taiwan New Taipei City Road No. 179 North four Xinzhuang District 13 Building 6 Applicant before: AIYI BIOTECHNOLOGY CO., LTD. |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1206334 Country of ref document: HK |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20170421 Address after: Taiwan district and Chinese Taipei city built eight road 189, 2 floor Applicant after: Three sun and moon biotechnology Limited by Share Ltd Address before: China Taiwan Taipei City Neihu district road six lane 135, 11 civil rights section No. 4 Lane Applicant before: Huang Xushan |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1206334 Country of ref document: HK |